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Normal human metabolism is a well-integrated process involving the whole 
organism. It can be disturbed in very different situations, either in true inborn errors 
of metabolism or in acquired situations where abnormal cells or tissues produce 
abnormal metabolites, or during critical illness, when overwhelming metabolic stress 
is present in normal tissues. These situations may share common pathogenetic 
mechanisms and metabolic markers, and their closer knowledge could provide 
new approaches for treatment or diagnosis.
Objectives
This thesis had two objectives, both dealing with biochemical changes in situations 
where significant metabolic perturbations occur.
(1) To study thiol metabolism in children with several inborn errors of metabolism 
(organic acidaemias, hypoglycaemic episodes, mitochondrial diseases, 
homocystinuria) and in cell culture models, where similar metabolic conditions 
are created. Thiol levels and thiol redox status, serving multiple metabolic and 
regulatory purposes, could be affected in inborn errors of metabolism following 
inappropriate nutrition and compromised energy metabolism. Possible changes 
in thiol status and the associated increase in oxidative stress could have an 
important role in the development of complications in these diseases. Changes 
in thiol status could even offer therapeutic potential, as thiol levels can be 
influenced by diet or medication.
(2) To investigate end products of metabolism in infants with cow’s milk allergy 
(CMA) as metabolic markers of  inadequate nutrition in early childhood and 
altered intestinal microbial metabolism. Eventually, these changes could 
provide a novel diagnostic tool.
Methods
Children (n = 36) with inborn errors of metabolism (either organic acidaemia, 
mitochondrial disease, homocystinuria or diagnosed hypoglycaemia) were enrolled 
from Great Ormond Street Hospital, London, UK. Infants (n = 35) with diagnosed or 
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suspected cow’s milk allergy participated from Skin and Allergy Hospital, Helsinki, 
Finland. Patients referred to the same clinic but in whom no disease was observed 
formed the respective control groups. 
Plasma and erythrocyte non-protein thiols (glutathione and cysteine) as well 
as thiols in cultured human fibroblasts, HEPG2 and 293T cells were measured 
with a liquid chromatography –based method. Mass spectrometry was used for 
quantification of urinary excretion of end products of metabolism in CMA patients. 
Activities of enzymes related to thiol metabolism in human erythrocytes were studied 
in spectrophotometric assays.
Results
(1) Patients with organic acidaemias, hypoglycaemic episodes, mitochondrial 
diseases and homocystinuria had altered levels of plasma non-protein thiols 
glutathione and cysteine, and their plasma thiol redox status was indicative 
of oxidative stress even in the absence of acute critical illness.
(2) Patients with CMA had increased urinary excretion of  several metabolic end-
products.  These changes in urinary metabolic profile may reflect inappropriate 
nutrition, altered intestinal bacterial metabolism or increased intestinal 
permeability.
Conclusions
(1) Thiol metabolism is altered in several inborn errors of energy and nutrient 
metabolism. The changes in thiol redox status are suggestive of oxidative 
stress, which seems to play a role in the pathogenesis of these diseases or 
their complications.
(2) With further research, the changes in thiol levels and thiol redox state could 
have therapeutic implications; thiol status can be affected by dietary sulphur 
amino acid intake and thiol antioxidant supplementation.
(3) CMA is associated with measurable changes in urinary levels of end products 
of metabolism, which may be seen as markers of inadequate nutrition. With 
further research, these changes could provide an innovative new approach to 
the diagnosis of CMA
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4. INTRODUCTION
Metabolism is a delicately coordinated entity of chemical reactions. By these 
reactions, the organism produces the necessary elements for tissue maintenance, 
growth and reproduction, excretes toxic and residual compounds and maintains 
a balance between energy and nutrient intake, consumption and storage. Human 
metabolism can be viewed and studied either from the perspective of the whole 
organism, certain tissues or individual cells or cell populations. In an experimental 
setting, cultured cells give information about metabolism in individual cells or cell 
populations. Evaluation of plasma values is more suggestive of the overall metabolic 
situation at a given time, whereas quantification of end products excreted in urine 
gives an overview of long-time metabolic homeostasis in the whole organism (Maher 
et al. 2007). 
Metabolism can be disturbed in either inherited or acquired situations. At 
present, the majority of inherited metabolic diseases cannot be cured, and many 
of them have a fatal course. When available, the treatment often remains supportive 
and experimental. These diseases cause severe disturbances in growth and 
development and often present with episodes of acute metabolic decompensation. 
The detailed pathogenesis of these severe, even fatal, complications is often unclear, 
making possibilities for treatment few. New information about the pathogenesis 
of the complications in these diseases could be valuable, as it could provide new 
therapeutic approaches. 
Research on metabolic diseases may also be useful for a thorough understanding 
of normal human metabolism. Many metabolic disturbances in originally “non-
metabolic” diseases may have common pathogenetic factors with inborn errors of 
metabolism. Metabolism and nutrition are also closely related, as situations with 
disturbed metabolism are often associated to inappropriate nutrition, and poor 
nutrition leads to metabolic changes. Studying metabolic disturbances may, then, 
also reveal the underlying nutritional problem.
This thesis has focused on biochemical changes in different situations with 
significant metabolic disturbances. These changes are seen as metabolic markers 
of the underlying pathogenetic processes, offering new insights into disease 
mechanisms and, with further research, even therapeutic potential. 
14
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5. REVIEW OF THE LITERATURE
5.1. INBORN ERRORS OF METABOLISM
Inborn errors of metabolism are rare congenital diseases that are mainly due to a 
genetic defect of enzymes or cofactors participating in a certain metabolic pathway 
or the transport of metabolites within a cell or between cells. This can lead to
1. Accumulation of substrate (e.g. accumulation of methylmalonate in 
methylmalonyl-CoA mutase deficiency, methylmalonic acidaemia)
2. Loss of end product (e.g. hypoglycaemia following defects in 
gluconeogenesis, or defective oxidative ATP energy production in 
mitochondrial diseases)
3. Accumulation of normally minor metabolites (e.g. accumulation of 
propionic acid in methylmalonic acidaemia)
4. Secondary metabolic consequences (acidosis, ketosis, accumulation 
of lactate or ammonia). These may obscure the underlying metabolic 
disturbance and cause diagnostic confusion.
The ensuing symptoms often appear during the neonatal period but sometimes 
only later, often in the childhood, giving rise to late-onset forms. Also adult-onset 
inherited metabolic diseases exist; in these diseases, the symptoms are often chronic 
and progressive. Most inborn errors of metabolism, however, affect infants and 
young children. 
One of the major problems in understanding inherited metabolic disorders is 
their enormous variability. Individual inherited metabolic diseases are very rare 
but, collectively, they form an important group of diseases especially amongst 
paediatric diseases. Many different types of inherited metabolic diseases can give 
rise to similar symptoms and cause diagnostic confusion; clinical phenotypes of 
single diseases may also vary. Rather than classifying metabolic disorders according 
to their pathogenesis or to the most striking but often varying clinical features they 
have (Clarke 2006), a useful approach is to divide metabolic disorders according to 
their main presentation in clinically oriented pathogenetic subgroups (Saudubray 
et al. 2006). This approach is also suitable for guiding therapeutic measures.
1. Disorders of “intoxication type”, where the accumulation of a substance 
that is toxic when present in excess is the main clinical problem (e.g. urea cycle 
disorders, aminoacidopathies such as phenylketonuria, organic acidaemias, 
metal disorders, sugar intolerances). An initial symptom-free period is 
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followed by intoxication-like symptoms, which may be acute or chronic, but 
often intermittent and provoked by acute illness or dietary changes. The 
treatment, if available, relies on nutritional therapy. A special diet may reduce 
the accumulation of the toxic substance (e.g. avoiding phenylalanine and 
its precursors in phenylketonuria). Sometimes, cofactor supplementation 
may boost residual enzymatic activity to allow sufficient enzymatic function 
(e.g. the B12 –responsive form of methylmalonic acidaemia). It may also 
be possible to enhance the excretion of the accumulating metabolite by 
nutritional supplements or medication (e.g. the use of sodium benzoate in 
hyperammonaemia), or to replace a critical intermediary metabolite and thus 
reduce the accumulation of other metabolites in a specific metabolic pathway 
(e.g. supplementation of citrulline in some urea cycle disorders).
2. Disorders of energy metabolism, either mitochondrial defects 
(disorders of the respiratory chain, Krebs cycle and pyruvate oxidation as 
well as defects in fatty acid oxidation and ketone bodies) or diseases affecting 
cytoplasmic energetic processes (e.g. gluconeogenesis and glycolysis defects, 
hyperinsulinism).  In these disorders, the possibilities for treatment depend 
on the nature of the defect in energy production; most mitochondrial defects 
are untreatable, whereas defects of gluconeogenesis and glycolysis are often 
less severe and amenable to treatment.
 3. Disorders involving intracellular organelles and storage, interfering 
with synthesis or breakdown of complex molecules. Examples include lysosomal 
storage diseases, peroxisome diseases and inborn errors of cholesterol synthesis. 
These disorders have a chronic and progressive course, and are unrelated to 
diet or other environmental factors. Previously, these disorders were also 
untreatable, but currently, enzyme replacement therapy is available for 
some lysosomal storage diseases (Fabry, Gaucher and Pompe diseases and 
mucopolysaccaridoses I, II and VI; reviewed by Lachman in 2011).
In this series of studies, patients with three distinctive groups of metabolic 




In addition, patients with homocystinuria were studied, and their previously 
unpublished results are reported.
17
5.1.1. ORGANIC ACIDAEMIAS
Organic acidaemias, also called organic acidurias, are rare inborn errors affecting 
mainly the catabolism of branched chain amino acids (valine, leucine and isoleucine); 
hence the term branched-chain organic acidurias, which include as well the 
“classical organic acidurias” (isovaleric, methylmalonic and propionic acidurias) 
as maple syrup urine disease (MSUD), 3-methylglutaconic acidurias, 3-hydroxy-
3-methylglutayl-CoA lyase deficiency, 3-methylcrotonylglycinuria  and some rarer 
conditions. The incidence of all individual organic acidaemias separately or the 
overall incidence of organic acidaemias are not exactly known, but any organic 
acidemia is estimated to occur in about 1: 40 000 live births (Zytkovicz et al. 2001). 
When risk populations such as children with symptoms suggestive of metabolic 
disease are selectively screened, organic acidemias seem to be among the relatively 
common metabolic diseases with a prevalence as high as 3% (Wajner et al. 2009). 
Individual organic acidaemias are rare; the combined incidence of the three classical 
organic acidaemias (propionic, methylmalonic and isovaleric) has been reported to 
be less than 2: 100 000 births in the general population with newborn screening 
(Dionisi-Vici et al. 2006).  As these disorders are genetic and inherited in a recessive 
autosomal manner, their incidence varies greatly between different populations 
and can reach even 1:2000 or 1:5000 for propionic acidaemia (Al Essa et al. 1998).
5.1.1.1. Metabolic basis 
Due to metabolic blockage following the specific enzyme deficiency in the catabolism 
of isoleucine, leucine or valine, short chain carboxylic acids and their metabolites 
accumulate in tissues and are excreted in excess in urine (Figure 1). Methylmalonic 
and propionic acidaemias are not only due to defects in the catabolism of branched-
chain amino acids, as propionic acid is also derived from the metabolism of proteins, 
nucleic acids and lipids and produced by intestinal bacteria, and methylmalonic 
acid is derived from propionic acid (Figure 1) (Sweetman and Williams 2001, 
Fenton et al. 2001, Ogier de Baulny and Saudubray 2002, Dionisi-Vici et al. 2006). 
Studies with stable isotopes have confirmed that about 50% of the accumulating 
propionate and methylmalonate are derived from amino acid catabolism; bacterial 
metabolism in the gut and catabolism of odd-chain fatty acids in lipids account for 
the rest in equal amounts (Leonard 1997).
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Figure 1. Origins of isovaleric acid (IVA), methylmalonic acid (MMA) and propionic acid (PA) and most 
important enzymes involved in the development of isovaleric, methylmalonic and propionic acidaemias.
Organic acids (IVA, MMA and/ or PA) are derived from the catabolism of branched-chain amino acids, fats, 
bacterial metabolites and nucleic acids. Following metabolic blockage in the enzymatic breakdown of IVA, 
MMA or PA, the corresponding organic acid and its acyl CoA derivative accumulate. 
All intermediates are not illustrated.
1 Isovaleryl-CoA dehydrogenase (EC 1.3.99.10)
2 Propionyl-CoA carboxylase (EC 6.4.1.3)
3 Methylmalonyl-CoA mutase (EC 5.4.99.2).  B12 –derived adenosylcobalamine needed as cofactor.
5.1.1.2. Clinical presentation
Organic acidaemias have an unpredictable course ranging from a severe and often 
fatal neonatal onset form to milder chronic forms with neurological problems, 
developmental delay and failure to thrive (Sweetman and Williams 2001; Fenton 
et al. 2001). The central nervous system is especially affected, with presentations 
ranging from lethargy to seizures and cerebral palsy or ataxia, and patients often 
present structural brain abnormalities (Wajner 2004). Also other organ systems may 
be affected, and patients may have hepatopathy, cardiomyopathy and signs of bone 
marrow dysfunction. Organic acidaemias often have a fatal course; the mortality 
rate in patients with either isovaleric, methylmalonic or propionic acidaemias was 
51% in a 20-year follow-up study (Dionisi-Vici et al. 2006).
Although the genetic basis and the origin of accumulating metabolites in 
organic acidaemias are known, the pathogenesis of many complications, including 
neurological deficits and episodes of acute metabolic crisis, remains unclear. The 
unexplained and unexpected nature of these complications and their poor correlation 
to known metabolic parameters, such as the blood concentration of organic acids, 
makes the clinical management of organic acidaemias very challenging. Some of the 
pathogenetic mechanisms of specific organic acids will be discussed in the following 
sections, and the role of oxidative stress in these diseases is reviewed in 5.3 and 5.5.
19
5.1.1.3. Diagnosis 
The diagnosis of organic acidaemias relies on identification of the accumulating 
organic acids, either in plasma, urine or cerebrospinal fluid, mainly by gas-liquid 
chromatography and mass spectrometry (GLC-MS). For diagnostic confirmation, 
determination of the specific enzyme activity in cultured fibroblasts or peripheral 
leucocytes is useful. Genetic diagnosis is available for known mutations in some of 
the conditions. Prenatal diagnosis is possible by GLC-MS determination of organic 
acids in the amniotic fluid, if the genetic defect is not known (Ogier de Baulny and 
Saudubray 2002). However, even in early-onset severe forms, the symptoms of 
organic acidaemias are unspecific and easily misinterpreted for infection or other 
acute illness, delaying the diagnosis. Newborn screening for organic acidaemias, 
performed by tandem mass spectrometry, may be used, but the long-term effects of 
newborn screening to the prognosis of organic acidaemias are unknown (Dionisi-
Vici et al. 2006).
5.1.1.4. Treatment 
The treatment of organic acidaemias consists of minimising the accumulation of 
the abnormal metabolites by dietary restriction of branched-chain amino acids, and 
the acute treatment of complications and periods of metabolic decompensation. 
In addition, specific treatment is available for cobalamin (vitamin B12) -responsive 
forms of methylmalonic acidaemia, and carnitine may be useful for facilitating the 
excretion of propionic acid metabolites and to prevent carnitine deficiency following 
conjugation reactions to carnitine. In propionic and methylmalonic acidaemias, 
intermittent antibiotic treatment by metronidazole in order to suppress propionate 
production by the intestinal flora, which accounts for 25% of propionate production 
(Leonard 1997) seems to be helpful (Ogier de Baulny 2002). As catabolism of odd-
chain fatty acids in lipids also results in propionic acid formation, prolonged fasting 
and other states promoting lipolysis should be avoided and treated promptly in 
propionic and methylmalonic acidaemias (Leonard 1997).
5.1.1.5. Isovaleric acidaemia (OMIM 243500)
Isovaleric acidaemia (IVA) is caused by a deficiency in the function of the apoenzyme 
of the mitochondrial enzyme isovaleryl-CoA dehydrogenase (EC 1.3.99.10). The 
defect leads to accumulation of isovaleric acid, 3-hydroxyisovaleric acid and 
N-isovalerylglycine and, following conjugation to carnitine, also isovaleryl carnitine. 
Free IVA is toxic, but formation of N-isovalerylglycine and isovaleryl carnitine leads 
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to formation of less harmful and soluble metabolites (Ogier de Baulny and Saudubray 
2002). Although the mechanism of IVA toxicity is not completely understood, it 
seems to be related to an impairment of mitochondrial energy metabolism and 
maintenance of membrane potential; in experimental animals, IVA administration 
inhibited citric acid cycle and disrupted neuronal Na+K+ATPase function (Ribeiro 
et al. 2007, Ribeiro et al. 2009).
Patients with isovaleric acidaemia present either with an acute neonatal onset 
form with uncontrollable metabolic acidosis, or with a late-onset chronic and 
intermittent form with recurrent episodes of ketoacidosis (Sweetman 2001).
5.1.1.6. Methylmalonic acidaemia (OMIM 25100, 251100, 251110, 277410 )
Methylmalonic acidaemia (MMA) is genetically more heterogeneous than other 
organic acidaemias. It is caused by defects in either methylmalonate metabolism 
(OMIM 25100), with decreased or absent methylmalonyl-CoA mutase (EC 5.4.99.2) 
function, or cobalamin (vitamin B12) metabolism. Cobalamin is needed for the 
synthesis of adenosylcobalamin, which is a cofactor for methylmalonyl-CoA mutase, 
a mitochondrial enzyme needed for methylmalonate breakdown. As expected from 
its heterogeneous origins, the clinical picture of MMA is extremely variable, ranging 
from an asymptomatic condition to a severe neonatal onset disease with metabolic 
acidosis. Patients with MMA due to defects of the translocation and intracellular 
synthesis of the active forms of cobalamin often also have elevated homocysteine 
levels (Fenton et al. 2001), as cobalamin –derived methylcobalamin is needed as 
a cofactor for methionine synthase which normally regenerates methionine form 
homocysteine. Patients with cobalamin –dependent forms of MMA are often also 
cobalamin-responsive and have clinical improvement and decreased MMA levels 
with B12 therapy (Fowler et al. 2008).
Patients with methylmalonic acidaemia often have several metabolic 
derangements (e.g. hyperammonaemia, hypoglycaemia, acidosis and 
hyperglycinaemia) that cannot directly be explained by the metabolic block 
following methylmalonyl-CoA mutase deficiency. The acidosis is not only due to 
the accumulation of MMA, which is a weak acid, and levels no higher than 3 mmol/l 
in plasma have been reported. Instead, it appears that the inhibitory effects of MMA 
to gluconeogenesis and mitochondrial energy metabolism lead to the development 
of ketosis, which further aggravates the acidosis (Oberholzer et al. 1967, Fenton et 
al. 2001).
Accordingly to the poorly understood metabolic abnormalities, the pathogenesis 
of complications and especially the neurological sequelae in methylmalonic 
acidaemia are somewhat obscure. Also the exact mechanism of toxicity of MMA is 
incompletely understood, although it seems to be related to defects in mitochondrial 
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function. Methylmalonate gives intracellularly rise to malonate, which interferes with 
mitochondrial energy metabolism by inhibiting succinate dehydrogenase (complex 
II of the respiratory chain) (McLaughlin et al. 1998). In addition, methylmalonate has 
direct toxic effects to mitochondrial energy production by inhibiting dicarboxylate 
carrier and, thus, mitochondrial succinate uptake (Mirandola et al. 2008).
5.1.1.7. Propionic acidaemia (OMIM 606054)
Propionic acidaemia (PA) is due to defects in the propionyl coenzyme A carboxylase 
(EC 6.4.1.3) gene, either in its a- or b-subunit. This mitochondrial enzyme requires 
biotin as a cofactor, and also inherited errors of biotin metabolism can lead to 
defects in propionyl CoA carboxylase function and accumulation of propionic acid 
(Fenton et al. 2001).
Patients have protein intolerance and suffer from periodic metabolic crises 
with lethargy, vomiting and ketosis, and they often have developmental delay and 
other neurological sequelae including seizures. Patients also suffer from recurrent 
complicated infections suggestive of immune deficiency, and they may have leuko- 
and thrombocytopenia suggestive of bone marrow suppression. 
Some of the accumulating propionic acid may be used for fatty acid synthesis, 
resulting in abnormal, odd-number fatty acids. During a catabolic state and active 
lipolysis, they may contribute significantly to the patient’s propionic acid load (Ogier 
de Baulny and Saudubray 2002).  Also propionate produced by intestinal microbiota 
influences propionate levels in patients. In addition to an excess of propionic acid, 
patients also have hyperglycinaemia and –uria, and additional metabolic features 
such as hyperammonaemia are often present. The metabolic pathways underlying 
these features are incompletely understood, as are the exact mechanisms of 
propionic acid toxicity. Some toxic effects of propionate to mitochondrial function 
have been reported (Stumpf et al. 1980), so it is reasonable to assume that similar 
mechanisms than those shown in MMA (described previously) could also underlie 
the toxicity of PA.
5.1.2. HYPOGLYCAEMIA
Rather than a specific metabolic disease, hypoglycaemia is a serious metabolic 
disturbance accompanying many other metabolic and originally non-metabolic 
diseases. Premature neonates and neonates who are either small or large for 
gestational age are at risk for hypoglycaemia; in addition, hypoglycaemia occurs as 
an iatrogenic factor in diabetic patients on insulin treatment. It is also a complication 
and symptom in a number of inborn errors of metabolism such as disorders of 
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fatty acid oxidation, gluconeogenesis defects, glycogen synthetase deficiency, and 
hyperinsulinaemia (Saudubray et al. 2002, Sperling 2004, Saudubray et al. 2006). 
In addition, hypoglycaemia may occur in previously healthy individuals during 
infections or prolonged fasting and/ or malnutrition. Indeed, all children are prone 
to develop low blood glucose if fasted for a sufficiently long period; hypoglycaemic 
children may only represent the low end of the physiologic range of tolerance to 
fast (Sperling 2004). 
5.1.2.1. Definition of hypoglycaemia
The definition of hypoglycaemia is arguable and age-dependent (Cornblath 1990); 
for instance, neonates often have lower blood glucose than children or adults, and 
blood glucose concentrations as low as 1.7 mmol/l (30 mg/dl) may be considered 
normal during the first hours of adaptation to postnatal life (Committee on Fetus 
and Newborn and Adamkin 2011). Whole-blood glucose levels below 2.7 mmol/l 
(50 mg/dl) are often considered hypoglycaemic (Sperling 2004); this corresponds 
to 10-15% higher plasma glucose levels.  No clear-cut limits exist; neurological 
symptoms due to low blood glucose (neuroglycopaenic symptoms) occur at plasma 
glucose below 3.0 mmol/l (54 mg/dl) (Cryer 2007). It is particularly difficult 
to establish a cut-off value for normal blood glucose in children, as low glucose 
concentrations are sometimes seen in healthy asymptomatic children following 
prolonged fasting (Cryer 2009). 
5.1.2.2. Eects of hypoglycaemia to the central nervous system
The central nervous system is especially vulnerable to prolonged or recurrent 
hypoglycaemic episodes such as those encountered in metabolic diseases. The 
pathogenesis of their complications is not thoroughly understood, but it seems 
evident that these are caused by more complex mechanisms than simply a failure 
of intracellular energy production. Presumably, hypoglycaemia leads to a sequence 
of adverse events causing cellular damage and, eventually, cell death; these events 
involve glutamate receptor activation and exitotoxicity, free radical production, 
mitochondrial permeability transmission and other cellular sress responses (Auer 
2002, Suh et al. 2007). 
Previous in vitro or experimental studies on hypoglycaemia have been performed 
in very low glucose concentrations that rarely occur in clinical situations. For 
instance, cells of different origin have been grown in a medium containing no glucose 
(Coleman et al. 2007, Suh et al. 2007), or experimental animals allowed to reach 
a profound hypoglycaemic coma with isoelectric EEG (Suh et al. 2007,  Suh et al. 
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2008). In addition, in experimental settings, in vivo hypoglycaemia is often achieved 
by insulin administration; insulin prevents lipolysis and ketogenesis (Sperling 2004) 
and deprives the central nervous system from its alternative fuel, ketone bodies. 
Thus, the effects of insulin-induced (or hyperinsulinaemic) hypoglycaemia to the 
central nervous system may differ from hypoglycaemia with low insulin levels.
Clinical studies with samples taken during hypoglycaemia are few. Studying 
patients with subnormal blood glucose would be needed to be able to understand 
pathogenetic mechanisms from hypoglycaemia occurring in more common and 
clinically relevant stress situations, such as during acute illness or prolonged fast.
5.1.3. MITOCHONDRIAL DISEASES
Mitochondrial diseases are inborn errors of energy metabolism due to a defect in 
either mitochondrial (mtDNA) or nuclear DNA coding for proteins of the respiratory 
chain or other molecules needed for mitochondrial function (DiMauro and Schon 
2003, Rahman and Hanna 2009). The most important function of mitochondria 
is oxidative phosphorylation, i.e. aerobic production of ATP energy in the electron 
transport chain; hence, some authors use the term mitochondrial diseases when 
referring only to disorders of oxidative phosphorylation (mutations in proteins of 
the electron transport chain). However, a broader definition such as the above, 
encompassing also other conditions with compromised mitochondrial function, 
is often used (DiMauro and Schon 2003). With a prevalence estimated between 
1:5000 (Debray et al. 2008) and 1:10 000 (Shoffner 2001), mitochondrial diseases 
form an important group amongst inherited metabolic disorders.
Due to their heterogenous origin and the importance of mitochondria in almost 
all tissues, mitochondrial diseases have extremely variable clinical pictures with 
manifestations in different and often multiple target tissues.  As mitochondrial 
diseases are, above all, disorders of energy metabolism, tissues with highest energy 
requirement, such as skeletal muscle, heart or liver, are most often affected. The most 
frequent clinical manifestation is that of a complex neurological or neuromuscular 
disease. However, symptoms may arise from any tissue and, depending on the 
particular mitochondrial disease, very specific tissues may be affected. This suggests 
that other, more complex mechanisms than simply a global failure to produce 
ATP energy are involved, but these mechanisms are currently poorly understood 
(DiMauro and Schon 2003).
The phenotype of those mitochondrial diseases caused by mutation in mtDNA 
is particularly varying due a phenomenon known as heteroplasmy. MtDNA has 
a high mutation rate, and as a result, the hundreds of mitochondria within a 
single cell may differ from each other – the cell is heteroplasmic (Wallace 1999). 
Following cell division, the wild-type and mutant-type mitochondria are distributed 
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differently to subsequent cells; often, a certain threshold number of pathologic 
mitochondria is needed to have clinical symptoms in a particular tissue. Due to the 
same phenomenon, also the inheritance pattern may vary, as mtDNA is maternally 
inherited – the symptoms of the progeniture depend on the percentage of mutant 
mitochondria they have inherited.
As the origin of the symptoms and the involvement of particular tissues in 
mitochondrial diseases is largely unknown, also their treatment remains supportive 
and symptomatic at best. None of the therapeutic approaches has been proven 
effective  (Chinnery et al. 2006) with the only exception of a favourable response 
to coenzyme Q10 (ubiquinone) administration in primary coenzyme Q10 deficiency 
(Quinzii et al. 2007, Rahman and Hanna 2009). 
5.1.4. HOMOCYSTINURIA
Homocysteine is derived from the sulphur amino acid methionine by 
S-adenosylmethionine –dependent transmethylation. Under normal circumstances, 
homocysteine may be further transsulphurated to cysteine or remethylated back to 
methionine (see 5.6.3; Mudd et al. 2001). The metabolic pathway for homocysteine 
production from methionine may exist in most cells and tissues, but the liver has 
the most central role for homocysteine production by transmethylation (Williams 
and Schalinske 2010).
Homocystinuria is an inborn error of metabolism in which homocysteine 
and its derivatives accumulate due to a metabolic blockage in these enzymatic 
pathways. Homocystinuria is most often caused by decreased or absent enzyme 
activity of cystathionine β-synthase (CBS, EC 4.2.1.22), which catalyses the 
first and irreversible step in homocysteine transsulphuration. The accumulating 
intracellular homocysteine is transported to blood; only a small proportion of 
plasma homocysteine then remains in the reduced, free, homocysteine form, and 
the rest forms homocystine disulphides or mixed disulphides with cysteine or protein 
sulphydryl groups (Mudd et al. 2001). 
Homocystinuria due to CBS deficiency (OMIM 236200) is inherited as an 
autosomal recessive trait, but multiple underlying genetic defects exist, causing 
genetic and clinical heterogeneity. In addition, several rare defects in other enzymes 
participating to homocysteine metabolism have been identified, including several 
cobalamin-responsive forms of combined homocystinuria and methylmalonic 
acidurias (OMIM 277410; OMIM 277400; OMIM 277380) with defects in vitamin 
B12 (cobalamin) metabolism. The incidence of homocystinuria due to CBS deficiency 
has been reported to be 1: 344 000, making it a relatively rare inborn error of 
metabolism, but as the disease is inherited in a recessive autosomal manner, it is 
more frequent in some populations (Yap and Naughten 1998).
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The clinical picture of homocystinuria due to CBS deficiency is varying, but patients 
often present starting from their second decade of life with mental retardation, 
skeletal abnormalities, ophthalmologic problems (dislocation of the lens, myopia) 
and thromboembolic vascular diseases (Mudd et al. 1985). Many CBS-deficient 
patients are responsive to pyridoxin (vitamin B6) therapy; B6 is needed as a cofactor 
for CBS, and responsive patients have some residual CBS activity that can be boosted 
with cofactor supplementation. In others, treatment consists of dietary restriction 
of homocysteine precursors and treatment of complications (Yap and Naughten 
1998, Mudd et al. 2001).
5.2. ACQUIRED SITUATIONS WITH DISTURBED METABOLISM
Disturbances of metabolism can occur in other clinical situations than actual 
metabolic diseases. Metabolic problems typical of metabolic disease may occur 
in acquired conditions with secondarily disturbed metabolism in cells or tissues; 
for example, lactic acidosis may develop during critical illness following impaired 
peripheral circulation leading to compromised energy production. The well-
coordinated metabolic balance between normal cells and tissues may be disrupted 
in the presence of malignant cells, which override metabolic control mechanisms. 
In addition, changes in the function or composition of certain metabolically active 
tissues, such as the liver or the intestinal bacterial flora, may have major metabolic 
consequences even if the original problem is not truly “metabolic”.
Nutrition and metabolism are closely related. Problems in either one lead to 
perturbations in the other. In many inherited diseases of metabolism, nutrition is 
inadequate due to a metabolic blockage making normal nutrients harmful to the 
patients and causing further metabolic burden (e.g. protein, or branched-chain 
amino acid, intolerance in organic acidaemias). In a similar way, in certain other 
clinical conditions, metabolic problems may be due to an inadequate nutrition, 
either if nutrition is insufficient or if nutrients are poorly tolerated. 
In this series of studies, cow’s milk allergy (CMA) in early infancy has been used 
as a model of a situation where inappropriate nutrition leads to metabolic changes. 
CMA in infancy was chosen as it is a common clinical condition; in addition, as 
milk is the main nutrient in this age group, CMA may be seen a prototype of food 
intolerance. The possible metabolic changes in CMA could, then, be due to the 
infant’s metabolic responses to poorly tolerated food or, as reviewed in 5.2.2, to the 
metabolic abnormalities of the altered intestinal microbiota in CMA. 
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5.2.1. COW’S MILK ALLERGY: GENERAL CONCEPTS
Cow’s milk allergy is an immunological reaction to one or more of cow’s milk 
proteins. It is often considered to be the prototype of food allergy, and it affects 
2 – 2.5% of children during the first years of life in European countries (Mansueto 
et al. 2006) and in the USA (Sampson 2004); prevalences as high as 7.5% have been 
reported (Venter et al. 2006, Vandenplas et al. 2007). According to the underlying 
immunologic mechanism, CMA, as other food allergies, can be divided into IgE-
mediated and non-IgE –mediated forms (Sicherer 2002), which also influences the 
diagnosis and prognosis. 60% of children with CMA have IgE-mediated reactions 
(Sampson 2004), and these tend to persist until later age; however, CMA is most 
often a temporary condition, as 80% of infants with CMA regain tolerance to cow’s 
milk protein by the age of 3 years (Kneepkens and Meijer 2009).
The diagnosis of food allergies, including CMA, is challenging. No specific and 
sensitive diagnostic tests are available despite the high prevalence of these diseases. 
Especially during the first year of life, symptoms are often unspecific and general 
(Kneepkens and Meijer 2009), and almost half of the patients show a delayed type 
of reaction (Vandenplas et al. 2006), causing diagnostic confusion.
Several diagnostic procedures including skin prick tests (SPT) and allergen-
specific IgE (sIgE) antibodies exist for IgE –associated CMA; however, they 
only measure sensitisation to the allergen and half of the sensitised children 
are not food allergic (Kneepkens and Meijer 2009). Thus, the laborious and 
resource-requiring double-blind placebo-controlled oral food challenge remains 
the gold standard (Sicherer 2002, Sampson 2004, Vandenplas et al. 2007, 
Kneepkens and Meijer 2009); it is also the only reliable diagnostic test for 
non-IgE –mediated CMA. 
5.2.2. ALTERED INTESTINAL MICROBIOTA AND PERMEABILITY IN CMA 
Intestinal flora is a tissue with substantial size and enormous metabolic activity 
(Nicholson et al. 2005); indeed, the 1014 bacteria of the human gut exceed 10-fold 
the number of cells in the human body (Penders et al. 2007), and its metabolic 
activity is equal to that of liver (Ouwehand 2007). Intestinal microbiota contribute 
to digestive and absorptive processes and their metabolites are also absorbed by the 
host: they fermentate undigested carbohydrates and non-digestable polysaccharides 
to short-chain fatty acids (SCFA), are involved in vitamin B (pantothenic acid, 
biotin, folic acid and vitamin B12, or cobalamin) production and vitamin K synthesis 
(Guarner and Malagelada 2003, Guarner 2006). They also participate in ion and 
water absorption, and their metabolites affect cholesterol and bilirubin metabolism 
and some catabolic processes (degradation of beta-aspartylglycine, mucin etc.). In 
addition, bacterially produced SCFAs, especially butyrate, seem to have trophic 
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properties on the colonocytes of the intestinal epithelium (Salminen et al. 1998, 
Goossens et al. 2003, Nicholson et al. 2005).
5.2.2.1. Altered composition of intestinal microbiota 
The intestinal microbiota is different in patients with food allergies as compared to 
healthy individuals (Bjorksten et al. 1999, Bjorksten et al. 2001, Kirjavainen et al. 
2001, Kalliomäki et al. 2001a), Gore et al. 2008). Allergic children have higher counts 
of clostridia and less bifidobacteria in their faeces than do nonallergic children, and 
those of the allergic children with positive IgE-antibodies to food allergens appear to 
have even higher clostridia counts (Sepp et al. 2005). As the differences in intestinal 
microbiota precede the development of food allergies (Kalliomäki et al. 2001 a), 
Sepp et al. 2005), they do not seem to be completely secondary to the disease itself.
5.2.2.2. Altered metabolism of intestinal microbiota
Not only the composition but also the function, the metabolic activity, of intestinal 
microbiota is altered in atopic diseases (Norin et al. 2004, Ouwehand et al. 2007, 
Sandin et al. 2009). These changes precede allergic symptoms. Children with high 
risk for allergy had higher amounts of SCFA produced in bacterial metabolism in 
their faeces than do children with low allergy risk, and also their faecal SCFA profiles 
differed, there being less i-butyric and (i-) valeric acids in children later developing 
allergy (Kalliomäki et al. 2001 a), Norin et al. 2004, Sandin et al. 2009).  In a 
similar way, in infants already having diagnosed allergy, the faecal SCFA composition 
showed less (i-) valeric, (i-) butyric and propionic acids, and higher levels of i-caproic 
acid (Böttcher et al. 2000). 
In order to understand changes in intestinal microbiota, studying the metabolism 
of intestinal microbiota may be a more applicable method than identifying its 
composition by searching for different bacterial species. Less than 40% of intestinal 
bacteria can be cultured outside the gastrointestinal tract (Guarner and Malagelada 
2003, Sandin et al. 2009), whereas the metabolites of the unculturable species may 
still be recognised.
5.2.2.3. Increased intestinal permeability 
The intestinal inflammatory reaction secondary to the food allergy (Mansueto et 
al. 2006) causes changes in intestinal permeability by disrupting the intestinal 
epithelial barrier (MacDonald et al. 2005). Accordingly, children with food allergies 
28
have been shown to have increased intestinal permeability to some compounds (e.g. 
lactulose) (Jackson et al. 1981, Laudat et al. 1994) and permeability to bacterial 
metabolites may well be increased in a similar way. Interstingly, there may be 
a two-way interrelationship between intestinal epithelial integrity and intestinal 
microflora, as it appears that the intestinal microbiota influence gut epithelial 
integrity (Isolauri et al. 2002, MacDonald and Monteleone 2005). 
In summary, in a condition where there are concomitant changes in the 
composition and metabolic activity of the intestinal flora and in the intestinal 
permeability, measurable metabolic changes might also be shown in the host. Many 
end products of metabolism from human cells as well as from intestinal bacteria are 
excreted in the urine (Nicholls 2003, Nicholson et al. 2005, Walsh 2006). Following 
changes in intestinal permeability or intestinal microbiota, urinary excretion of end 
products of metabolism could thus be altered, which would offer new possibilities 
for the diagnosis of CMA or other food allergies; changes in intestinal microbiota 
have been shown to be reflected to urinary metabolite excretion (Nicholls 2003). 
Indeed, several studies have applied these findings to the diagnosis of food allergy 
(Laudat et al. 1994; Andre et al. 1987), but results from other studies are conflicting 
(Kuitunen et al. 1994; Catassi et al. 1995). In addition, it has been stated that only 
very small amounts of bacterial metabolites are noticeable in urine (Salminen et 
al. 1998)
Table 1. Mechanisms underlying possible metabolic changes in CMA.
References are marked with a superscript number in the table and listed in numeric order under 
the table.
PATHOLOGIC FEATURE ASSOCIATED WITH FOOD 
ALLERGY OR ATOPY
POSSIBLE INFLUENCE TO HOST METABOLISM
Intestinal inflammation with
•	Disruption of the intestinal epithelial barrier1 
•	 Increased intestinal permeability to some  
 compounds2, 3, 4, 5 
Permeability to normally unabsorbed 
compounds possibly reflected in urinary 
excretion of metabolic end-products
Dierent composition of intestinal microbiota 6 
•	 More clostridia 
•	 Less bifidobacteria
Dierent microbiota produce dierent SCFA 
patterns
Composition of intestinal microbiota influences 
intestinal epithelial integrity and absoption 12, 1 
Dierent metabolic activity of intestinal 
microbiota 7 
•	 Elevated i-caproic acid in faeces 8
•	 Decreased propionic, (i)-butyric and  
 (i)-valeric acids in faeces 8, 9, 10, 11
Dierent SCFA patterns produced by intestinal 
microbiota
•	 Noticeable in host metabolism13
•	 Reflected in urinary excretion of metabolic  
 end-products13
1 MacDonald and Monteleone 2005; 2 Jackson et al. 1981; 3 Andre et al. 1987; 4 Dupont et al. 1989; 5 
Laudat et al. 1994; 6 Sepp et al. 2005; 7 Ouwehand et al. 2007; 8 Böttcher et al. 2000; 9 Kalliomäki 
et al. 2001 a); 10 Norin et al. 2004; 11 Sandin et al. 2009; 12 Isolauri et al. 2002; 13 Nicholson et al.2005.
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5.2.3. PROBIOTICS AND CMA
Probiotics are defined as live micro-organisms that, when administered in adequate 
amounts, have beneficial effects on the health and well-being of their host, regardless 
of their mechanism of action (Sanders 2008, Rijkers et al. 2010); this definition 
includes both commensal bacteria in the human gastrointestinal tract and genetically 
modified or biotechnology-derived species. As the use of probiotics in prevention and 
treatment of disease is the target of increasing scientific and commercial interest, 
even the definition of probiotics is in constant progress; earlier broader definitions 
included as well the products that these micro-organisms secrete  (Paganelli et 
al. 2002), whereas originally, the term “probiotic” was used only to describe 
those micro-organisms and substances that had beneficial effects to the intestinal 
microbial balance (Fuller 1991). In therapeutic purposes, widely used probiotic 
strains include different species of lactobacilli (e.g. Lactobacillus rhamnosus GG, 
Lactobacillus acidophilus, Lactobacillus reuteri) and the Bifidobacterium species.
As the changes in gut microbiota in and preceding atopic diseases are becoming 
widely acknowledged, increasing interest has been drawn to the possible beneficial 
effect of probiotics in the treatment (Majamaa and Isolauri 1997, Viljanen et al. 2005, 
Weston et al. 2005, Brouwer et al. 2006, Taylor et al. 2007, Grüber et al. 2007) 
and in the prevention (Kalliomäki et al. 2001 b), Kalliomäki et al. 2003, Taylor et 
al. 2007, Kukkonen et al. 2007) of allergic diseases. This far, consensus has not 
been reached; the positive results obtained so far have also been questioned, and 
in some recent studies, probiotics have had no effect to atopic diseases (Matricardi 
et al. 2003, Brouwer et al. 2006, Taylor et al. 2007, Grüber et al. 2007). Some of 
the conflicting results may be explained by different study designs used, including 
different probiotic strains, different duration of the treatment and also the selection of 
study subjects. Immunologic mechanisms underlying allergic diseases are different 
and currently, it seems that probiotics are mainly effective in the treatment and 
prevention of IgE –mediated food allergies (Savilahti et al. 2008). In addition, it 
seems that their effect is, at best, moderate.
The exact mechanisms underlying the potential beneficial effects of probiotics in 
atopic diseases are unknown. It is generally thought that probiotics induce a low-
grade inflammation in the gut and this, in turn, promotes tolerance to food allergens 
and downregulates allergic immune responses by inducing an immunologic 
shift favouring non-allergic Th1-type immunologic reactions, interleukin-10 and 
interferon-g secretion (Savilahti et al. 2008). In addition, probiotics enhance 
intestinal barrier function, and some of their beneficial effects may be due to changes 
in the metabolic activity of intestinal microbiota following probiotic colonisation 
(Madsen et al. 2001, Rosenfeldt et al. 2004, Goossens et al. 2003). 
Previous research has shown that the changes in the intestinal permeability 
following food allergies may be reversible (Dupont et al. 1989, Jalonen 1991), but it 
is unclear whether the disturbances in intestinal flora could also be reversible (e.g. 
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by probiotic treatment). It is known, however, that colonisation by probiotic strains 
after probiotic administration is transient, lasting only for weeks after cessation of 
probiotic treatment (Goossens et al. 2003, Savilahti et al. 2008). 
Understanding the metabolic abnormalities associated to CMA and, eventually, 
the metabolic mechanisms of probiotic action in CMA could provide new approaches 
to the diagnosis and treatment of CMA.
5.3. REACTIVE OXYGEN SPECIES, OXIDATIVE STRESS AND   
 ANTIOXIDANTS
5.3.1. CONCEPTS 
Any chemical species capable of independent existence that has one or more 
unpaired electrons in an atom or molecular orbital is a free radical (Halliwell and 
Gutteridge 2007).  As a single electron usually makes the species highly reactive 
and thus unstable, biologic molecules are mainly nonradicals. (Halliwell 1991). In 
biological systems, the hydroxyl radical (OH•) is the most reactive; it is capable of 
oxidising, i.e., receiving an electron from, most redox-active biomolecules.
Reactive oxygen species (ROS) are highly reactive metabolites of oxygen and some 
of them are also free radicals. Others, having no unpaired electrons, can be defined 
as nonradicals, but they are capable of high reactivity or free radical formation 
under special circumstances. An example of a nonradical reactive oxygen species is 
hydrogen peroxide (H2O2), which may form the extremely reactive hydroxyl radical 
in the presence of transition metals, such as iron. 
Fe2+    +    H2O2    →    Fe
3+    +    OH•    +    OH- 
The Fenton reaction: A hydroxyl radical is formed from the nonradical 
hydrogen peroxide in the presence of transition metals (here, iron). 
An even broader concept is reactive species (RS), which encompasses not only 
oxygen-derived radicals and nonradicals, but also reactive nitrogen species (RNS) 
such as nitric oxide (NO•) and peroxynitrite (ONOO-), as well reactive chlorine, 
bromine or sulphur species. Both ROS and RNS are known to play a role in human 
diseases; however, as some of the RNS, such as peroxynitrous acid (ONOOH) and 
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peroxynitrite (ONOO-) are also metabolites of oxygen and could thus be classified 
as reactive oxygen species, the term ROS is often exclusively used in biomedical 
literature. 
In the course of normal metabolism, ROS are continuously produced, and 
antioxidant systems (see 5.3.3) guard the organism against the oxidative damage 
that the reactive species are able to cause. Oxidative stress can be understood as an 
imbalance between these two counterparts, as an environment favouring oxidative 
reactions and deficient in reducing agents (Halliwell 2007). In principle, oxidative 
stress may result either from excessive free radical formation, impaired antioxidant 
defences, or both to some extent. 
Reactions between ROS and biomolecules are part of normal metabolism; they 
serve multiple metabolic and regulatory purposes. ROS are involved in intra- and 
intercellular signalling through redox-regulated ion channels and transcription 
factors (Sen 1998), and they play a crucial role in regulation of cell survival and 
apoptosis via mitochondrial calcium release (Sen 1998, Halliwell and Gutteridge 
2007, Decuypere et al. 2011). A moderate amount oxidative stress promotes 
survival in cell cultures (Burdon 1995), and in a similar way, an unusually oxidised 
environment is created in the endoplasmic reticulum on purpose to promote 
disulphide formation during protein folding (Halliwell 2000).
5.3.2. OXIDATIVE DAMAGE
When ROS are formed in excess, they damage biological structures by irreversibly 
oxidising them. All biomolecules are potential targets for oxidative damage, and 
some end products of different types of biomolecules subjected to oxidative damage 
may be measured in order to estimate oxidative damage (see 5.3.4). 
As reducing a radical involves the transfer of an electron from another substance, 
which is, in turn, oxidised, these reactions have a tendency to continue as chain 
reactions. An example of this is lipid peroxidation, in which lipids are oxidised in 
a self-propagating reaction, giving rise to new lipid peroxide radicals.
5.3.3. ANTIOXIDANT SYSTEMS
An antioxidant is a substance that prevents or delays oxidation of its substrate, 
which can be almost any molecule found in living cells. An antioxidant is capable of 
this action even when present at low concentrations as compared to the substrate 
(Halliwell 1991; Halliwell 2007). Antioxidants can function either in the first line 
of defence by preventing the formation of reactive oxygen species, and making the 
already formed reactive oxygen species inactive – “scavenging” them – or, failing this, 
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by repairing the already produced oxidative damage (Halliwell 1990). In addition, 
the compartmentalisation of ROS-producing reactions inside the cells (such as the 
localisation of the enzymes of the electron transport chain in the mitochondrial 
membrane) can be viewed as an antioxidant mechanism.  These mechanisms are 
summarised in Table 2.
Antioxidant systems mainly operate in collaboration with each other. Thus, 
superoxide dismutase is needed for disposal of superoxide, but the reaction 
produces hydrogen peroxide, which is removed by the action of catalase or 
glutathione peroxidase. To interrupt the chain reaction of lipid peroxidation (see 
5.3.2), a-tocopherol, or vitamin E, is oxidised to a-tocopheryl radical, which is then 
reduced back to protective a-tocopherol by vitamin C, which is, in turn, recycled by 
glutathione (Sies 1991, Cheeseman and Slater 1993).  It is important to notice that 
these examples are simplifications and result from in vitro evidence (Young and 
Woodside 2001, Halliwell 2007); in living organisms, antioxidant systems interact 
in a complex way to assure an optimal response to oxidative stress.
Table 2. Dierent mechanisms of antioxidant function
(Halliwell 1991, Halliwell and Gutteridge 2007)
MECHANISM OF ACTION EXAMPLE FUNCTION
Prevention of or
decrease in ROS 
production








Binding of transition metal ions





Disposal of H2O2, other peroxides
Removal of ROS by 
being oxidised prior 




Ascorbic acid (vitamin C)
Oxidation of GSH to glutathione 







Ascorbic acid and GSH
Reduction of GSSG to GSH
Production of NADPH (reducing 
power for GR)
Ascorbic acid restores 
a-tocopherol, and GSH restores 
ascorbic acid
Repair of oxidative 
damage
GSH, a-tocopherol
DNA repair systems, e.g.
• DNA glycosylase enzymes
• Xeroderma Pigmentosum -
  proteins
Chain-breaking antioxidants in 
lipid peroxidation
Base excision repair (removal of 
oxidatively damaged DNA bases)
Nucleotide excision repair  
(removal of oxidative DNA lesions 
such as 8OHdG)
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5.3.4. MEASURING OXIDATIVE STRESS 
Oxidative stress, the imbalance between free radical production and antioxidant 
capacity, is a dynamic state prevailing in a biological organism.  It is not possible to 
find a single and direct marker for oxidative stress. In principle, free radical formation 
and antioxidant systems could be studied separately to gain an understanding on 
their interrelationship. However, free radicals are, by definition, extremely reactive 
and short-lived species; techniques for their direct measurement in living systems by 
electron spin resonance have been developed, but are only of limited use. Radicals 
can also be detected by different techniques of radical trapping, which measure the 
more stable products of reactions between radicals and trap molecules, such as the 
formation of hydrogen peroxide (Abuja and Albertini 2001). 
Antioxidant systems can be studied in a wide number of different tissues, but 
the interpretation of results may be problematic. A decrease in antioxidant levels 
can be due to an increase in its consumption, a decrease in its production, or both, 
and an increase in oxidative stress may either increase antioxidant levels or, when a 
extensive oxidative stress is present and cellular response mechanisms fail, decrease 
them. Antioxidants mainly function together and in successive reactions; measuring 
their steady-state concentrations only gives an idea of the net changes that have 
occurred. The consequence of depletion of a particular antioxidant participating in 
a chain reaction is not easily predictable. Additional complicating factors include 
differences in antioxidant systems and function between different tissues. 
To solve these problems, techniques for measuring the overall antioxidant 
status in a particular tissue have been developed; such total antioxidant capacity 
assays measure the ability of a biological sample, e.g. a body fluid, to resist lipid 
peroxidation, and this ability is then compared to a known antioxidant (Abuja and 
Albertini 2001). In addition, expression of genes coding for proteins needed in 
antioxidant response can be studied, if relevant tissues are available for analysis. 
A useful approach for understanding oxidative stress in living systems is to 
study oxidative damage, as this gives indirect evidence of either excess free radical 
formation or deficient antioxidant supplies. Identification of oxidatively damaged 
structures may also be clinically relevant in order to target therapeutic measures. The 
use of oxidatively damaged structures as markers of oxidative stress is summarised 
in Table 3.
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Table 3. Oxidative damage to dierent cellular structures.
(DeZwart et al. 1999 and Halliwell and Gutteridge 2007)
GC Gas chromatography
HPLC High-pressure liquid chromatography
HPLC-ED High-pressure liquid chromatography with electrochemical detection





EXAMPLE OF QUANTIFICATION METHOD
Lipids
Peroxidation of fatty acids, giving 
rise to
 Aldehydes (e.g. MDA, HNE)
 Isoprostanes
 Exhaled hydrocarbons
Detection of thiobarbituric acid –reactive 
species (TBA-RS) by spectrophotometry 
or HPLC
Detection of F2 –isoprostanes from 
arachidonic acid by GC- or HPLC-MS




Loss of thiol groups
Other changes to amino acids 
Carbonyl assay (reaction with 2,4-DNPH); 
most widely used
Thiol group staining; Ellman’s reagent 
e.g. HPLC detection of o-tyrosine 
Nucleic acids 
(DNA)
Oxidised purine or pyrimidine 
bases
Strand breaks





Incorporation of labelled bases, 
immunodetection of DNA fragments
8-nitroguanine or 5-guanidino-4-
nitroimidazole measurement
GC-MS, HPLC-ECD –based quantification 
or immunoassay 
Adherence to gene-specific probes after 
removal of oxidised bases 
5.3.5. OXIDATIVE STRESS AND DISEASE: CAUSE OR CONSEQUENCE?
The toxic effects of oxygen have been known for centuries, but the concept of oxidative 
stress and the disease-causing potential of free radicals were first established when 
studying radiation injury (Gerschman et al. 1954). Half a century later, it was 
stated that oxidative stress, either in the form of excessive free radical production 
or impaired antioxidant defences, or both, occurs whenever cells and tissues are 
damaged (Halliwell and Gutteridge 2007). Oxidative stress has been associated to 
a wide range of acute or chronic disease states (e.g. retinopathy and respiratory 
distress syndrome in premature newborns, atherosclerosis, ischemia-reperfusion 
injury, neurodegenerative disorders, malnutrition), and the relationship of oxidative 
stress to aging has been intensively studied (Gil del Valle 2010, Seo et al. 2010, 
Decuypere et al. 2011). 
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This rather universal approach to oxidative stress has also been questioned (Sanz 
and Stefanatos 2008), since it is difficult to prove causality between oxidative 
stress and disease. Obviously, at some point of any disease process, cellular defence 
mechanisms against any harmful substance will fail; the coexistence of oxidative 
damage and a disease process does not necessarily indicate that oxidative stress 
has been a major causal factor throughout the development of the specific disease. 
Thus, when speaking about the interrelationship of oxidative stress and diseases, it 
may be more reasonable to concentrate on those diseases where oxidative stress has 
been shown to be present in earlier phases of the disease, thus truly contributing 
to the pathogenesis of complications.  
5.3.6. INCREASED FREE RADICAL PRODUCTION IN METABOLIC DISEASES 
Oxidative stress has been suggested to play a role in the pathogenesis of many 
metabolic diseases, such as the complications of diabetes mellitus (Abou-Seif and 
Youssef 2004, Gil del Valle et al. 2005), and in inborn errors of metabolism including 
mitochondrial diseases, hereditary tyrosinaemia, organic acidaemias (reviewed by 
Wajner et al. 2004), homocystinuria (Perna et al. 2003), phenylketonuria (Ercal 
et al. 2002) and maple syrup urine disease (Fontella et al. 2002). The mechanisms 
underlying increased free radical production in some inborn errors of metabolism 
are discussed below; the compromise of antioxidant systems and thiol metabolism 
are reviewed in 5.5.3.2 and in Table 5.
5.3.6.1. Organic acids interfere with mitochondrial ATP production
An increased free radical production following direct toxic effects of organic acids has 
been observed in vitro. Propionic and methylmalonic interfere with mitochondrial 
ATP production (Stumpf et al. 1980, Nakai et al. 1991, Dutra et al. 1993, McLaughlin 
et al. 1998, Okun et al. 2002) and disrupt intracellular ion homeostasis by inhibition 
of membrane Na+K+ATPase (Wyse et al. 1998, Wyse et al. 2000), resulting in 
an increase in free intracellular calcium, which favours free radical production 
(McLaughlin et al. 1998). 
These mechanisms and the following exitotoxicity have been of special interest 
when explaining the neuropathology of organic acidaemias. Brain tissue is very 
susceptible to oxidative stress following its high metabolic activity and oxygen 
consumption, and high concentrations of transition metals and auto-oxidisable 
molecules including some neurotransmitters are present (Wajner et al. 2004). 
Accordingly, many previous studies have associated other neurodegenerative 
disorders to mitochondrial dysfunction, energy failure, oxidative stress and 
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exitotoxicity acting in a synergistic way (reviewed by Wajner et al. 2004). With 
further research on oxidative damage and antioxidant status in organic acidaemias, 
similar mechanisms could well account for some of the unexplained neurological 
symptoms in these diseases.
The development of neurological problems in organic acidaemias has 
thus been studied to some extent. The pathogenesis of episodes of metabolic 
decompensation, the “metabolic crises”, that occur in organic acidaemias and have 
a major influence to the patients’ prognosis, is less clear. For instance, patients 
with organic acidaemias often present with pancreatitis, but the precipitating 
factors are not understood (Kahler et al. 1994). Interestingly, oxidative stress 
has been suggested to play a role in the development of pancreatitis in animal 
models (Schoenberg et al. 1995, Rau et al. 2000) and in humans (Schoenberg et al. 
1995, Park et al. 2003). In addition, deficiencies of antioxidant systems, including 
glutathione, have been noticed in association with pancreatitis (Rau et al. 2000, 
Park et al. 2003). Some patients with pancreatitis even respond to antioxidant 
therapy (Schoenberg et al. 1995, Schulz et al. 1999), even if this issue remains 
unclear (Mohseni Salehi Monfared et al. 2009). Thus, pancreatitis and oxidative 
stress might account for some of the episodes of metabolic decompensation in 
patients with organic acidaemias. This could also provide a target for treatment 
with antioxidants (Treacy et al. 1996).
5.3.6.2. Lack of energy and reducing power in hypoglycaemia lead to  
 mitochondrial dysfunction and excitotoxicity 
Under normal conditions, the production of free radicals is controlled and matches 
antioxidant supplies. When cellular energy metabolism is compromised, as occurs 
during hypoglycaemia, control mechanisms may fail and the production of free 
radicals in mitochondria and in cellular stress responses increase. Indeed, in 
experimental settings, hypoglycaemia, or glucose deprivation, has been associated 
with an increase in free radical production.  In these studies, experimental animals 
have reached profound insulin-induced hypoglycaemia with blood glucose 1 mmol/l 
(McGowan et al. 2006) or with isoelectric EEG (Ferrand-Drake et al. 1999, reviewed 
by Auer 2004, Suh et al. 2008); alternatively, cultured cells have been totally deprived 
of glucose with no glucose in the cell culture medium (Coleman et al. 2007, Suh et 
al. 2007) or chemical inhibition of glycolysis (Rego et al. 1999).  
The increase in free radical production during these rather extreme conditions 
has been related to a failure to maintain vital cellular control mechanisms. With 
depletion of energy supplies (Auer 2004) and lack of reducing power following 
inhibition of glycolysis (Rego et al. 1999) in profound hypoglycaemia mitochondrial 
dysfunction follows. This leads to “leakage” of mitochondria, an increase in 
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mitochondrial superoxide and hydrogen peroxide generation (McGowan 2006). 
In addition, cellular stress responses are activated, resulting in excitotoxicity and 
activation of cell death processes. Activation of neuronal glutamate receptors 
(Wieloch 1985, Suh 2007), increased intracellular calcium levels (Coyle and 
Puttfarcken 1993, Singh 2004), mitochondrial permeability transition (Ferrand-
Drake et al. 1999), altered redox status of the cell (Moley and Mueckler 2000) and 
activation of free radical –producing enzymes such as NADPH oxidase producing 
superoxide (Suh 2007) are crucial elements in a cascade causing increased ROS 
formation and ultimately leading to hypoglycaemic cell death. 
5.3.6.3. Dysfunctional mitochondria overproduce reactive species
Mitochondria are a major source of ROS even under physiologic circumstances; 1-2% 
of the molecular oxygen consumed in mitochondrial oxidative phosphorylation is 
metabolised to ROS following electron leakage from the respiratory chain. However, 
compromised function of the electron transport chain (ETC) has been shown to 
lead to an overproduction of reactive oxygen species (ROS) (Esposito et al. 1999, 
Wallace 1999, Chen et al. 2003). 
Accordingly, in patients with mitochondrial diseases (Wani et al. 2008) or in 
cultured cells with dysfunction of the mitochondrial respiratory chain (Pitkänen 
and Robinson 1996, Luo 1997), increased ROS production – measured as either 
increased hydroxyl radical or superoxide levels - has been observed. 
The overproduction of ROS by poorly functioning mitochondria is particularly 
detrimental, as ROS exposure has been shown to further compromise 
mitochondrial function by disrupting mitochondrial membranes and inactivating 
the iron-sulphur centres in complexes I, II and III of the electron transport 
chain (Bolanos et al. 1996, and reviewed by Wallace 1999). Mitochondrial 
dysfunction and increased ROS production thus seem to form a vicious cycle 
with one worsening the other.
5.3.7. ANTIOXIDANT THERAPY 
The amount of ROS production in a living organism is not readily influenced. In 
order to protect cells and tissues agains oxidative stress, the most logical therapeutic 
approach is to increase the amount of antioxidants available. Indeed, antioxidant 
therapy, and antioxidants in primary or secondary prevention of disease, has been 
the focus of innumerable studies. However, irrespective of the studied disease or 
antioxidant, nearly all of the clinical trials have had disappointing results (Chinnery 
et al. 2006, Steinhubl 2008, Bjelakovic et al. 2010, Bjelakovic et al. 2011). It seems 
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that the function and complex interplay between antioxidant systems in living 
organisms is not known to a sufficient degree to be able to target antioxidant therapy 
when it would be needed  (Bjelakovic et al. 2011).
As an exception to these unpromising results, in some situations where there is 
a selective deficiency of a specific antioxidant, antioxidant therapy has been shown 
to be effective. Examples of these include the treatment of severe GSH depletion in 
paracetamol (acetaminophen) intoxication with N-Acetylcysteine (Hinson 2010), 
which is a precursor of cysteine, the rate-limiting substance for GSH synthesis; or 
the supplementation of coenzyme Q10 (ubiquinone) to patients with a mitochondrial 
disease caused by primary coenzyme Q10 deficiency (Quinzii et al. 2007). 
Possibilities for thiol antioxidant treatment are reviewed in section 5.5.4.
5.4. THIOLS
5.4.1. STRUCTURE 
A thiol is a compound with a sulphydryl (-SH) group, also known as a thiol group, 
as the functional group. An aminothiol is a thiol associated to an amino acid. In 
humans, aminothiols are found in proteins and in other chemical structures, also 
known as non-protein thiols. The amino acid cysteine (CYSH, see also 5.4.2)  is the 
predominant aminothiol in the extracellular compartment, whereas intracellularly, 
the tripeptide glutathione (g -glutamyl-cysteinyl-glycine, GSH; see also 5.4.3) 
predominates (Jones et al. 2000). Glutathione may be oxidised with itself to form 
glutathione disulphide (GSSG), or with protein sulphydryl groups, forming mixed 
disulphides. In a similar way, cysteine is oxidised to cystine (CYSS), which contains 
a disulphide bond between two oxidised cysteine molecules.
In addition to cysteine and glutathione, homocysteine, which is an intermediate 
in sulphur amino acid metabolism and a precursor of cysteine (see 5.4.2 and 5.4.3), 
participates to thiol metabolism. Homocysteine is able to form mixed disulphides 
with cysteine and glutathione as well as with protein sulphydryl groups, and is part 
of plasma thiol pool (Ueland et al. 1996). Normally, plasma homocysteine levels 
are low as compared to cysteine levels, but in patients with homocystinuria or in 
some other pathologic conditions associated to high homocysteine levels, plasma 
homocysteine significantly participates in extracellular thiol-disulphide reactions 
and influences thiol redox status (Di Giuseppe et al. 2004).
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5.4.2. CYSTEINE 
Cysteine is an amino acid with a sulphydryl group, which allows it to form disulphides 
either with itself (yielding cystine) or with other thiols. Cysteine is not an essential 
amino acid in humans, as it can be synthesised from methionine, another sulphur-
containing amino acid. The transsulphuration pathway converting methionine 
to cysteine only takes place in the liver (Lu 1998) and consists of five sequential 
enzymatic reactions.
In addition to participating to protein synthesis as a nonessential amino acid, 
cysteine is also needed to produce non-protein structures, including glutathione, 
taurine and coenzyme A (Stipanuk et al. 2006). Cysteine is considered to be the rate-
limiting substrate for GSH synthesis (Deneke and Fanburg 1989, Lu 1998). Besides 
the synthetic processes, cysteine also has regulatory roles. Under physiological 
conditions, cysteine and methionine are the only amino acids showing reversible 
redox changes and thus participating to redox regulation of cellular functions (Blanco 
et al. 2007). As a result, both intra- and extracellular cysteine levels are tightly 
regulated and kept at a narrow range even when dietary cysteine intake varies 
(Stipanuk et al. 2006).
Some controversy has prevailed over the question whether the transsulphuration 
pathway is active already in the neonatal period and, hence, whether cysteine might 
be an essential amino acid for newborns (Levonen et al. 2000, Riedjik et al. 2007, 
Thomas et al. 2008). In addition, even in older children and adults, cysteine may be 
considered ”conditionally essential” (Tesseraud et al. 2009); the need for cysteine 
may exceed the transsulphuration capacity of the liver under stress conditions such 
as acute illness, when up to 40% of the increased cysteine need appears to be due 
to an increase in GSH synthesis (Metayer et al. 2008). Thus, a sufficient dietary 
intake of both methionine and cysteine seems to be needed to assure adequate GSH 
synthesis (Bray et al. 1993, Wu et al. 2004, Metayer et al. 2008), thereby coupling 
dietary protein intake, nutritional status and thiol homeostasis (see 5.4.3 and 5.5.3.1).
  
Cysteine (CYSH) Reduced glutathione (GSH)
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5.4.3. GLUTATHIONE: STRUCTURE, SYNTHESIS AND ITS REGULATION BY   
 CYSTEINE AVAILABILITY
Glutathione is a tripeptide formed from glycine, glutamate and cysteine with a 
g-carboxyl linkage between the glutamate and cysteine moieties (Hopkins 1929, 
Harington and Mead 1935). Glutathione is  present in virtually all eukaryotic cells 
in the millimolar range (Meister and Tate 1976). It is made in two consecutive 
ATP-consuming reactions from glycine, glutamate and cysteine catalysed by 
g-glutamylcysteine synthetase (GCS; EC 6.3.2.2), also called glutamate-cysteine 
ligase, and glutathione synthetase (GS; EC 6.3.2.3) (Meister and Anderson 1983) 
(Figure 2). The g-carboxyl linkage between glutamate and cysteine is important 
for GSH function, as it accounts for the intracellular stability of GSH (Meister and 
Tate 1976): only g-glutamyl transpeptidase, also called g-glutamyl transferase (gGT; 
EC 2.3.2.2), located on extracellular surfaces, is able to hydrolyse the bond. GCS 
activity is rate limiting for GSH synthesis, and the enzyme is feedback inhibited by 
GSH (Meister and Anderson 1983, Stipanuk et al. 1992). 
Cysteine is often considered the rate-limiting substrate for GSH synthesis 
(Deneke and Fanburg 1989, Lu 1998), as in plasma, glycine and glutamate are 
normally found in abundance (Stein and Moore 1954) as compared to more limited 
cysteine supplies. Moreover, the Km value of GCS for cysteine is close to intracellular 
cysteine levels, whereas intracellular glutamate levels clearly exceed the Km of GCS 
for glutamate (Lu 1998). Under special circumstances (e.g. in preterm babies, during 
foetal growth, in patients with sepsis, systemic inflammation or intense haemolysis, 
and during inadequate protein intake), however, glycine supplies may become a 
limiting factor for GSH synthesis (Jackson et al. 1987, Wu et al. 2004, Jackson et 
al. 2004). 
It seems that cysteine availability mainly controls the rate of GSH synthesis, 
although additional control mechanisms exist, as GSH itself feedback inhibits GCS 
activity (Meister and Tate 1976, Meister and Anderson 1983). In humans, GSH 
synthesis rates have been shown to increase when cysteine or its precursors are 
supplemented in various situations with low GSH levels (Wu et al. 2004, Badaloo et 
al. 2002), and blood GSH synthesis rates (but not GSH levels) diminish when sulphur 
amino acid intake is inadequate (Lyons et al. 2000). Cysteine supplementation has 
been shown to lead to increased blood or intracellular GSH levels in experimental 
animals (Tesseraud et al. 2008; Stipanuk et al. 2006). Even during low cysteine 
intake, utilisation for GSH synthesis has a priority in cysteine metabolism (Stipanuk 
et al. 1992).
The nutritional aspects of cysteine intake and GSH synthesis are discussed in 
more detail in 5.5.3.1.
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Figure 2. Glutathione synthesis and cysteine precursors. 
All the intermediates are not represented. Transmethylation of methionine to homocysteine is 
confined to the liver, whereas GSH synthesis from its precursors glutamate, cysteine and glycine 
takes place in virtually all tissues. The sequential conversion of methionine to cysteine via 





Glutathione is present in virtually all tissues and has multiple essential functions. 
Glutathione is, above all, involved in protection against toxic and harmful 
compounds, but it serves also other important purposes.
5.4.4.1. Glutathione in antioxidant reactions
GSH is an important intracellular antioxidant with a millimolar concentration. 
To scavenge (reduce) reactive oxygen species and peroxides, reduced glutathione 
can form disulphides with itself (oxidised glutathione i.e. glutathione disulphide, 
GSSG), or with other thiol compounds, including protein thiol groups (mixed 
disulphides). The oxidation of GSH is catalysed by different isoforms of glutathione 
peroxidase (GPx), although also non-enzymatic reactions are possible. Glutathione 
reductase (GR) can reduce GSSG back to protective GSH. The reducing power comes 
from NADPH formed in the pentose phosphate route where glucose-6-phosphate 
dehydrogenase (G6PDH), is the first and rate-limiting enzyme (Figure 3).
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Figure 3. The glutathione redox cycle
GSH reduced glutathione
GSSG oxidised glutathione (glutathione disulphide)
GPx glutathione peroxidase 
GR glutathione reductase
G6PDH glucose 6-phosphate dehydrogenase
ROOH peroxide 
ROH reduced peroxide
To reduce peroxides, GSH is oxidised to GSSG. The reaction is catalysed by GPx. GSH is restored, 
when GR catalyses the reduction of GSSG back to GSH. For the function of GR, reducing power 
from NADPH is needed. NADPH is regenerated in the pentose phosphate route, where the activity 
of G6PDH is rate-limiting. (Modified from Meister, 1988 and Meister, 1995).
5.4.4.2. Glutathione in conjugation reactions
Glutathione is involved in the detoxification of many compounds, which 
can be excreted as soluble glutathione conjugates, or be further degraded by 
g-glutamyltranspeptidase; the remaining cysteine conjugate is metabolised to 
mercapturic acid, which is excreted to urine. Glutathione transferase (GST) 
enzyme superfamily, formerly called the glutatione-s-transferases (Mannervik et 
al. 2005), catalyses the conjugation reactions between GSH and xenobiotics. In the 
conjugation reaction, the glutathionyl group (GS-) from glutathione is transferred to 
an electrophilic molecule (Whalen 1998, Mannervik 2005). Different GST enzymes 
may be divided into soluble GSTs encountered mainly in the cytosol (but also in 
organelles including mitochondria) and to mitochondrial GSTs operating inside 
mitochondria, and, finally, to microsomal GSTs which are integral membrane 
proteins (Mannervik 2005). The transcription of GST enzyme family is regulated by 
the same antioxidant response element (ARE) that also regulates gGCS and other 
antioxidant enzyme expression (Itoh et al. 2004); thus, the two protective functions 
of GSH  - conjugative and antioxidative - are coupled.  
5.4.4.3. Glutathione in cysteine storage and transport
In the extracellular compartment, glutathione acts as a reservoir and transporter 
of cysteine as it is less prone to oxidation than cysteine is. Circulating glutathione 
can be cleaved to yield cysteine by g-GT on external surfaces of cellular membranes 
(Meister and Tate 1976). The ability of diverse cell types to export GSH may also be 
related to this function of glutathione; GSH efflux provides other cells with cysteine 
(Meister and Anderson 1983), GSH only acting as a more stable transport form. 
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Also kinetic studies with stable isotopes show that the endogenous disappearance 
rate of GSH is responsible for the majority of whole body cysteine flux (Lyons et 
al. 2000), which further supports the idea of GSH functioning as a transport form 
of cysteine (Wu et al. 2004).
5.4.4.4. Glutathione in amino acid transport; the γ-glutamyl cycle
Tissues with high g-GT activity (e.g. renal tubular cells, lung type II alveolar cells, 
intestinal epithelial cells) use a common transport mechanism for amino acid and 
GSH uptake from blood (Meister and Tate 1976, Meister and Anderson 1983). 
The tripeptide GSH and an amino acid are cleaved by g-GT which is an integral 
membrane protein located on the extracellular surface. 
 GSH + amino acid    →    g-glutamyl amino acid + cysteinylglycine 
The resulting two dipeptides (g-glutamyl-amino acid and cysteinylglycine), may 
then be used for intracellular protein and GSH synthesis. Cysteinylglycine is 
further degraded extracellularly by dipeptidase to cysteine and glycine, which 
are then uptaken by the cell. The g-glutamyl-amino acid moiety, in turn, is degraded 
intracellularly by γ-glutamyl cyclotransferase to oxoproline, which is further 
metabolised to glutamate by 5-oxoprolinase. Thus, all three parts (glutamate, 
cysteine and glycine) needed for intracellular GSH synthesis have been reconstituted. 
The degradation of GSH on extracellular surfaces, followed by the uptake of 
amino acids by the cell and intracellular GSH synthesis is called the γ-glutamyl 
cycle. It is an important mechanism for regulating interorgan GSH homeostasis, as 
explained in 5.4.5.; in addition, it couples GSH to yet another vital cellular function, 
amino acid uptake.
5.4.4.5. Role of glutathione and intracellular thiol redox status in redox   
 signalling and regulation
Many intracellular signalling cascades, including enzymes, receptors, transport 
proteins or transcription factors are redox-regulated through oxidation and 
reduction of sulphydryl groups in protein cysteine residues (Dalle-Donne et 
al. 2007, Mieyal et al. 2008). Proteins can be directly redox-regulated through 
gGT
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conformational changes following oxidation or reduction of their sulphydryl groups. 
Redox control can also be exerted via redox-sensitive transcription factors, such 
as NF-kB, which are activated by reactive oxygen and nitrogen species (Ballatori 
et al. 2009 b). Glutathione is the most abundant intracellular non-protein thiol, 
and it is able to form mixed disulphides with protein thiol groups. This reversible 
process, called protein S-glutathionylation, is an important posttranslational 
modification and cellular regulatory mechanism, and it seems to function both as a 
response to oxidative stress (Fratelli et al. 2005) and under physiological conditions 
(Dalle-Donne et al. 2007). Thus, GSH has an important role in the maintenance of 
intracellular redox potential and the function of redox-sensitive control mechanisms, 
and this far, the multiple roles GSH serves in these critical processes are only being 
elucidated (Sabens et al. 2011).
5.4.4.6. Glutathione as a possible neuromodulator or neuroprotective agent
Glutathione has an important role as an antioxidant in the central nervous system, 
which is responsible of 20% of the oxygen consumption of the human body and 
thus a major source of ROS; indeed, GSH is critical for neuronal survival (Ballatori 
et al. 2009, b). However, it has been suggested that glutathione may also have 
other neuroprotective and neuromodulative roles, and that it may even act as a 
neurotransmitter (these hypotheses are reviewed by Janáky et al. 1999, Ballatori et 
al. 2009, b). It seems that GSH is both a ligand and a modulator of the glutamate 
NMDA receptor (Janáky et al. 1999, Oja et al. 2000, Ballatori et al. 2009, b), and 
that there may even be specific “GSH receptors” in the central nervous system 
(Janáky et al. 1999). 
5.4.5. INTERORGAN HOMEOSTASIS OF GLUTATHIONE; THE ROLE OF PLASMA  
 AND ERYTHROCYTE THIOLS
5.4.5.1. Interorgan, intercellular and intracellular glutathione homeostasis 
Most tissues and cell types are able to synthesise GSH. However, liver is essential for 
supplying GSH to the whole organism for two reasons: first, only liver can synthesise 
cysteine from methionine by the transsulphuration pathway (Lu 1998), thus 
providing the rate-limiting component for GSH synthesis, and, second, hepatocytes 
export GSH in large amounts to be then taken up into tissues with high g-GT 
activity, e.g. renal tubular cells or cells in jejunal villi (Meister and Anderson1983). 
In addition, hepatocytes also secrete GSH to bile; GSH is released to the intestine 
and its constituent amino acids are reuptaken in the enterohepatic cycle.  Also 
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other tissues are able to export GSH (Ballatori et al. 2009 a), but the role of liver 
is essential in supplying other tissues with GSH (Figure 4).
Glutathione is a hydrophilic molecule and cannot pass freely through cellular 
membranes. The transport of GSH from plasma to cells is coupled to amino acid 
uptake, and it mainly occurs via extracellular GSH cleavage to cysteinylglycine and 
g-glutamyl-amino acid moieties by g-glutamyl transpeptidase. These dipeptides can 
then be used for intracellular GSH synthesis and/ or protein synthesis (see 5.6.4). 
The activity of g-glutamyl transpeptidase determines the extent to which different 
cell types are able to import GSH from the extracellular space (i.e., from plasma, 
intestinal lumen etc.) (Meister and Tate 1976). Kidneys, with very high gGT activity, 
are responsible for most of GSH turnover (Lash 2009) in the body. Hepatocytes, 
in turn, have virtually no ɣGT activity, whereas in biliary epithelium, ɣGT activity 
is high. This reflects the liver’s central role in supplying GSH to other tissues rather 
than taking it up for its own use. In addition to the gGT-dependent GSH transport 
mechanism, kidneys seem to be able to take intact GSH from cell to cell, or from 
the extracellular space to the cell, across the basolateral membrane (Lash and Jones 
1984 and 1985, Lash 2009). This phenomenon has been a subject of debate (Ballatori 
et al. 2009 a), Lash 2009) and its physiological significance, as well as the exact 
structure of GSH transporters serving this purpose, remains unknown (Lash 2009).
In contrast to GSH import, the mechanisms of GSH export from cells are better 
understood. Some of the multidrug resistance –associated proteins (Mrp; Mrp-1 
and Mrp-2, possibly Mrp-4 and Mrp-5) have been identified as GSH transporters, 
and they are also able to export GSSG and glutathione S-conjugates (Ballatori et al. 
2009, a). GSH and GSSG export through Mrp and, probably, other transporters, 
is an important mechanism for controlling intracellular thiol redox status and cell 
survival.  Excess GSSG is exported during increased oxidative stress to maintain 
adequate GSH/GSSG balance (Jones 2002) and GSH export, in turn, may induce 
thiol redox changes triggering apoptosis (Hammond et al. 2007).
In addition to interorgan and intercellular homeostasis mechanisms, GSH 
is compartmentalised intraracellularly. Mitochondria have a separate GSH pool 
needed for local protection against ROS produced in oxidative phosphorylation. 
At least two different carrier proteins (the dicarboxylate and the 2-oxoglutarate 
carriers) transport cytosolic glutathione as intact GSH across the inner mitochondrial 
membrane (Lash 2006). Mitochondrial GSH status is an important determinant 
of mitochondrial function and ROS production, which further participate to the 
regulation of cell viability and signalling (Fernandez-Checa et al. 1998, Lash 2009).
Knowledge on GSH synthesis and levels in different tissues in vivo is incomplete, 
as GSH metabolism is complex and involves intracellular, intercellular and interorgan 
compartmentalisation (Wu 2004). Only fairly recently, the use of stable isotopes in 
order to study in vivo rates of GSH synthesis has given new information about GSH 
metabolism on the scale of the whole organism (Lyons et al. 2000, Wu et al. 2004).
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Figure 4. Interorgan transport of GSH.
The liver is able to synthesise cysteine and to export GSH. The liver provides other tissues with 
glutathione (and cysteine) via GSH release to plasma and bile.
The uptake of GSH in dierent tissues mainly depends on their gGT activity. GSH is degraded to 
its constituents for uptake and then resynthesised intracellularly in extrahepatic tissues. In order to 
maintain their GSH/GSSG redox status, cells may export GSSG. 
Plasma GSH mainly arises from the liver. Sources of plasma GSSG also include extrahepatic tissues 
such as erythrocytes and lungs that release GSSG into the circulation under oxidative stress.
5.4.5.2. Plasma glutathione: relevance, sources and function
Glutathione is predominantly an intracellular antioxidant and detoxifier; plasma 
GSH levels are very low, in the micromolar range (1-10 mmol/l) (Halliwell 1990). 
Although more stable than cysteine, also plasma GSH is relatively short-lived, 
with a half-time of a few minutes (Jones et al. 1998), and thus efficient uptake 
to cells by extracellular gGT activity is essential. Due to these characteristics, the 
analysis of plasma GSH is technically demanding. Even minor haemolysis during 
blood sampling or sample procession leads to an artefactual increase in plasma GSH 
levels, as erythrocyte GSH levels exceed plasma levels 500-fold, and immediate 
treatment of the sample is needed to avoid GSH oxidation.
Glutathione antioxidant enzyme activity is present also in human plasma, but 
it seems that plasma GSH levels are too low to truly participate to antioxidant 
defence in the extracellular compartment (Halliwell and Gutteridge 1990). Instead, 
the function of plasma glutathione seems to be related to amino acid transport and 
to the maintenance of extracellular thiol status. 
Plasma GSH largely arises from the liver (Meister 1988, Ookhtens and Kaplowitz 
1998), although many cell types release GSH to the extracellular space following 
cellular damage. This may further trigger apoptotic pathways by influencing 
intracellular thiol redox status (van den Dobbelsteen et al. 1996, Hammond et al. 
2007, Ballatori et al. 2009 a). In addition, under oxidative conditions, GSSG is 
actively transported from cells in order to maintain intracellular thiol redox balance 
(Jones 2002, Ballatori et al. 2009 a). GSH and GSSG export are mediated by the 
multidrug resistance –associated proteins (Mrps) and, possibly, other transporters 
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(Ballatori et al. 2009 a). This contributes to plasma total glutathione levels and 
plasma GSH/GSSG redox status. 
Thus, plasma GSH level reflects a complex interorgan metabolism and plasma 
GSH, as such, is certainly not an adequate measure of antioxidant defences or 
oxidative stress. Plasma GSH levels, however, probably reflect intracellular 
glutathione levels available for antioxidant defence as GSH release from cells 
depends on its intracellular concentrations (Jones 2002). Consequently, it has 
been postulated that plasma glutathione may represent glutathione levels in less 
accessible tissues (Pastore et al. 2003) and be an indicator of long-term GSH status 
in the organism (Taylor et al. 1992). Plasma GSH levels, however, represent the net 
sum of interorgan GSH metabolism, and changes in plasma GSH may not always 
be a reliable measure of GSH levels in cells or other tissues (Jones et al. 1998, Wu 
et al. 2004). 
Additional factors such as dietary uptake of sulphur amino acids, fasting, age and 
sex also influence plasma GSH levels to some extent (Blanco et al. 2007), although 
tight metabolic control exists to minimise changes in these crucial components of 
plasma thiol redox status (Stipanuk et al. 2006).
In summary, plasma GSH appears to arise mainly from the liver. Sources of 
plasma GSSG include also extrahepatic tissues such as erythrocytes and lungs that 
release GSSG into the circulation under oxidative stress (Adams 1983). Plasma GSH/
GSSG ratio could then, to some extent, express the balance between antioxidant 
capacities (liver GSH release) and the need for GSH in oxidative reactions (tissue 
GSSG export). 
5.4.5.3. Erythrocyte glutathione
As oxygen carriers, erythrocytes are continuosly exposed to high oxygen 
concentrations and thus susceptible to oxidative damage. Moreover, as anucleate 
cells, their ability to repair damaged proteins and lipids is limited. To face these 
challenges, erythrocytes are rich in antioxidant systems, including GSH and enzymes 
needed for its synthesis and antioxidant function (Kurata 1993). In order to maintain 
intracellular redox balance, erythrocytes excrete GSSG by an ATP-dependent active 
mechanism under situations of increased oxidative stress and thus contribute to 
plasma GSH/GSSG ratios (Lunn et al. 1979, Adams et al. 1983). 
In vivo studies on GSH kinetics have shown that erythrocytes have a high turnover 
rate for GSH, and indeed, in healthy human subjects, erythrocytes completely replace 
their GSH in 1.5 days, which represents nearly 10% of the GSH synthesis in the 
whole body (Lyons et al. 2000). Interestingly, even if erythrocytes have high GSH 
synthesis rates, they lack gGT activity (Srivastava 1976) and are thus unable to 
use the conventional way of extracellular GSH degradation for intracellular GSH 
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synthesis. Instead, erythrocytes transport the constituent amino acids cysteine, 
glycine and glutamate (in the form of glutamine) by specific sodium-dependent 
transporters (Raftos et al. 2010). Thus, erythrocytes are dependent on continuous 
amino acid supply for their antioxidant defences, and seem not to be able to profit 
from GSH supply from the liver.
5.4.5.4. Plasma cysteine and other plasma aminothiols
Reduced cysteine is the predominant low-molecular weight thiol in the extracellular 
compartment, including plasma (Ueland et al. 1996). Reduced cysteine, however, is 
only a small part of the total plasma cysteine pool, which includes reduced cysteine 
(3-4% of the total plasma cysteine pool), free oxidised cysteine (cystine, CYSS; or 
cysteine in mixed disulphides with other non-protein thiols, including GSH and 
homocysteine; 30% of total) and protein-bound cysteine (65% of total) (Ueland 
1995, Ueland et al. 1996).
Plasma cysteine has an important role in metabolic and regulatory processes 
by serving as a precursor for glutathione and being able to participate in redox 
reactions (see 5.4.6). As a result, the levels of plasma cysteine are tightly regulated, 
and excess cysteine is toxic. Also intracellular cysteine levels are subject to regulation, 
but the extracellular levels are kept at an even narrower range, varying from 80 
to 220 or 250 mmol/l (Ueland et al. 1996, Stipanuk et al. 2006). The liver has a 
central role for regulating plasma cysteine levels. This is also coupled to the liver’s 
ability to control GSH levels, GSH serving as a cysteine reservoir. By controlling the 
synthesis of cysteine from methionine, the synthesis of GSH from cysteine and the 
differential metabolic fates of cysteine (including synthesis of coenzyme A, taurine 
and inorganic sulphate), the liver acts a buffer against variations in plasma cysteine 
levels following changes in dietary cysteine intake (Stipanuk et al. 1992, Bella et al. 
1999, Stipanuk et al. 2006).
Plasma cysteine, plasma cysteinylglycine and plasma homocysteine in their 
reduced, free oxidised (“non-protein disulphide”) and protein-bound forms 
comprise the plasma redox thiol status, a dynamic system participating in 
regulatory processes and influencing intracellular functions (see 5.4.6). Of these, 
under normal conditions, plasma cysteine pool is by far the most important, as it 
exceeds the levels of homocysteine and cysteinylglycine pools about 20- and 10-fold, 
respectively (Ueland et al. 1996). When levels of homocysteine are elevated, also 
plasma homocysteine pool may be an important factor in determining extracellular 
redox status.
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5.4.6. THIOL REDOX STATE
5.4.6.1. Reduction potential, Eh
In order to describe the reductive or oxidative properties of GSH/GSSG or CYSH/
CYSS pool, which influence many cellular functions as described in 5.4.4, their 
electrochemical reduction potential (Eh) may be calculated, using the standard 
reduction potential (E0) for each reduction/ oxidation (redox) pair.
In general, a more negative E0, expressed in millivolts, indicates that the redox 
pair in question will, under standard conditions, be oxidised prior to one with a 
more positive E0. The “actual” reduction potential Eh is calculated from the E0 by 
the Nernst equation. It takes into account the ratio of the concentrations of the 
reduced and the oxidised pair of the couple and the temperature during the specific 
circumstances in question.
However, as in humans in vivo, temperature is fairly constant, instead of 
calculating redox potentials, it is informative to use only the ratio of concentrations 
of GSH to GSSG or CYSH to CYSS in order to express their redox state (Adams et al. 
1983). This approach is simpler and useful, but it does not allow direct comparison 
between different redox pairs (Jones et al. 2000). 
5.4.6.2. Role of thiol redox state: intra- and extracellular redox regulation and 
 signalling
Under physiological conditions, sulphur amino acids, i.e. extracellular cysteine/
cystine and intracellular GSH with its cysteine moiety, are the only amino acids that 
participate in reversible redox reactions (Blanco et al. 2007). These are essential 
for redox regulation and signalling. Thus, the role intracellular GSH/GSSG redox 
pair is an important determinant of intracellular redox status, influencing redox-
regulated protein conformation, transcription etc. (see also 5.4.4.5).
CYSH/CYSS, in turn, largely determines extracellular redox state, which may 
control intracellular processes by redox-mediated signalling via intracellular ROS 
production (Imhoff et al. 2009). In addition, the intracellular redox states of GSH/
GSSG and CYSH/CYSS are held at a considerably more reduced level than the ones 
in plasma, providing a reduced environment to intracellular processes (Jones et 
al. 2000).
In addition to CYSH/CYSS and GSH/GSSG, also homocyst(e)ine participates to the 
thiol status and has an important role especially in plasma, where its concentrations 
range from 5 to 12 mmol/l in healthy individuals, thus outnumbering the plasma GSH/
GSSG pool. Less than 4% of plasma homocysteine is in its reduced, free, form (Ueland 
1996) and the rest is in homocysteine disulphide form (homocystine), in mixed 
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disulphides with plasma cysteine (homocysteine-cysteine disulphide) or bound to 
protein sulphydryl groups, thus influencing extracellular redox status.
5.4.6.3. Thiol redox state as an indicator of oxidative stress or antioxidant   
 reserves
In addition to its physiological role in redox regulation, thiol redox state can also 
be studied as an indicator of oxidative stress and antioxidant reserves. Changes in 
thiol redox state have been associated with many pathological states (Adams et al. 
1983, Jones et al. 2002, Imhoff et al. 2009). In human plasma, the redox state of 
glutathione (GSH/GSSG) is about 60 mV more reduced that that of plasma cysteine 
(CYSS/CYSH), and they both are considerably more oxidised than the redox states 
in tissues or cultured cells. (Jones et al. 2000, Jones 2002). Thus, intracellular 
environment is held at a more reduced state than extracellular fluids. 
The redox states of different thiol pools in human plasma (e.g. GSH/GSSG, 
CYSH/CYSS, cysteinylglycine/ its disulphides) are not equilibrated with each other. 
Instead, they are separately balanced so that the rate of thiol supply matches the rate 
of thiol oxidation in plasma, thus providing information about antioxidant/ oxidant 
status (Jones et al. 2000). The differences in redox states of plasma thiol pools 
suggest that the redox state of plasma cysteine/cystine pool represents oxidative 
events of plasma thiols – the first line of defence, oxidised before other thiols – 
whereas that of glutathione is indicative of plasma antioxidant capacity and the 
supply of antioxidants from tissues – the second line of defence (Jones et al. 2002). 
When studying plasma thiol redox states, as is mainly done when studying 
human thiols in vivo, the main component is plasma CYSH/CYSS pool. The sources 
of changes in plasma GSH/GSSG redox state are much more complex and less 
interpretable (Blanco et al. 2007) and, in addition, more prone to artefactual results, 
as plasma GSH levels are low.
5.4.6.4. Glutathione and thiol status may reflect viability of cells and tissues
Glutathione and other thiols thus have many central roles in regulation, protection 
and even nutrition. Glutathione is more than an antioxidant or detoxifier; 
intracellular GSH, extracellular cysteine and protein thiol groups form a dynamic 
system known as the thiol status of the organism, which participates in the regulation 
of cellular redox environment and thus influences a broad spectrum of cellular 
functions and metabolic processes. All these roles taken together, glutathione and 
the thiol status may be seen as metabolic markers of well-being in cells or tissues 
with regard to their nutritional state, the accuracy of antioxidant defence, and cellular 
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viability including cell proliferation, differentiation and apoptosis (Pastore et al. 
2003, Ballatori et al. 2009 b).
5.5. THIOLS IN HEALTH AND DISEASE
5.5.1. PHYSIOLOGIC VARIATION IN THIOL LEVELS AND THIOL REDOX STATE
Plasma and, possibly, tissue thiol levels and redox state vary according to several 
physiologic factors, including at least age, sex, diet and physical activity (Table 
4). More oxidised plasma thiol redox state prevails during the newborn period 
(DiGiuseppe 2004) and in the elderly (Jones et al. 2002), and men have more 
reduced plasma thiols (Blanco et al. 2007). The redox state of plasma cysteine 
and/ or glutathione has a diurnal pattern (Blanco et al. 2007); plasma free reduced 
cysteine increases after meals, which reduces plasma cysteine redox state, and a 
similar phenomenon is seen with a 6-hour delay in plasma GSH concentrations 
and redox state. Dietary sulphur amino acid intake, also when adequate, influences 
plasma thiol redox states (Park et al. 2010, Jones et al. 2011), even if plasma thiol 
levels are tightly controlled by the liver (Stipanuk et al. 2006). In addition, other 
life style factors (e.g cigarette smoking, physical activity) may play a role (Moriarty 
et al. 2003, Banerjee et al. 2003).
5.5.2. FROM INBORN ERRORS OF GLUTATHIONE METABOLISM TO ACQUIRED  
 STATES WITH LOW GLUTATHIONE LEVELS 
The multiple roles of GSH are illustrated in the rare known conditions with inborn 
errors in GSH metabolism in humans (Meister and Anderson 1983, Meister 1991, 
Wu et al. 2004). In a defect in g-GCS function (OMIM #266130), also known 
as 5-oxoprolinuria, g-glutamylcysteine is produced in excess because of absent 
feedback inhibition from GSH, and this is further metabolised to 5-oxoproline, 
which accumulates leading to potentially lethal acidosis. The patients also have 
haemolysis and a neurodegenerative disease, probably due to absence of GSH 
antioxidant activity. All known inborn errors of GSH metabolism are associated to 
severe neurological problems. This clearly reflects the antioxidant, neuroprotective 
and, possibly, neuromodulative roles GSH plays in the central nervous system 
(Ballatori et al. 2009 b). In addition, patients with defects in GR, G6PDH, GCS 
and GS activity all present with haemolysis (Meister 1991), emphasising the priority 
of GSH in erythrocyte antioxidant defence (see 5.4.5.3).
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Transgenic animals with deficiencies in GSH synthesis or function have been 
developed, essentially showing the same problems than patients with these defects 
(Halliwell 2007). In addition, GSH synthesis has been inhibited by specific agents 
in experimental animals. These studies show that the most important effect of 
extreme GSH deficiency is mitochondrial damage, and that newborn animals are 
more sensitive than older ones (Meister 1991).
In addition, multiple acquired situations with low GSH levels, mainly in plasma, 
have been reported, including malnourishment, critical illness, HIV infection, 
diabetes mellitus and Parkinson’s disease (reviewed by Ballatori et al. 2009 b.). It 
is, however, difficult to define to which state GSH deficiency is inherent to the disease 
process itself, and which of the symptoms or metabolic problems may be related 
to GSH deficiency. A well-known and clinically relevant example of an acquired 
situation with GSH deficiency is paracetamol (acetaminophen) intoxication, where 
the electrophilic (oxidising) metabolite formed from acetaminophen is scavenged 
by GSH, leading to GSH depletion in the liver. This is followed by oxidative stress, 
mitochondrial dysfunction and, ultimately, liver cell necrosis and liver failure (James 
et al. 2003, Hinson et al. 2010).




Influence to thiol status Reference
Age 1. Increasing age (after 50 y) associated with 
more oxidised plasma thiol redox state
2. Newborn babies have more oxidised 
plasma thiols
1. Samiec et al. 1997; Jones et 
al. 2002; Blanco et al. 2007 
2. DiGiusepppe et al. 2004






1. a) Decreased tissue GSH in experimental 
animals on low-protein diet
1. b) Decreased erythrocyte GSH and GSH 
synthesis rates during low (but adequate) 
protein intake
2. Increased plasma CYSH and plasma 
CYSH/CYSS redox state more reduced with 
high sulphur amino acid intake
1. a) Taylor et al. 1992
1. b) Jackson et al. 2004
2. Park 2010
Day time Diurnal variation in thiol redox according 
to meal time (more reduced plasma CYSH/
CYSS after meals; followed by delayed 
reduction of plasma GSH/GSSG)







1. Exercise associated with increased thiol 
levels; strenuous and prolonged exercise 
with thiol oxidation  
2. Smokers have oxidation of plasma CYSH/
CYSS and GSH/GSSG
1. Banerjee et al. 2003
2. Moriarty et al. 2003
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5.5.3. THIOLS IN METABOLIC DISEASES
Metabolic diseases often cause serious problems in the energy metabolism of cells 
and tissues; this may impair the function of thiol antioxidant systems, which are 
dependent on continuous energy supplies. Patients with metabolic diseases may also 
have poor nutritional status including low dietary protein intake, which potentially 
affects thiol status dependent on sulphur amino acid intake. 
In addition to the possible impairment of thiol antioxidant systems, increased 
free radical production has been associated to many metabolic diseases including 
organic acidaemias, mitochondrial diseases, and homocystinuria. Increased free 
radical generation also seems to play a role in the pathogenesis of hypoglycaemic 
neuronal damage. The mechanisms involved are discussed in more detail in section 
5.3. If free radical generation is simultaneously increased, any compromise in thiol 
metabolism would be detrimental.
5.5.3.1. Protein intake and nutrition influence thiol status and glutathione synthesis
Decreased tissue GSH concentrations have been measured in experimental 
animals fed with a low-protein diet (Taylor 1992), and similar results have 
been seen in protein-energy malnourished human subjects. Patients with 
anorexia nervosa had low plasma glutathione (Zenger 2004), and children with 
kwashiorkor had low erythrocyte GSH synthesis rates (Reid 2000, Badaloo et 
al. 2002). Thus, low GSH in protein-energy malnourishment apparently results 
from an inability to synthesize enough GSH and not only from an increase in 
GSH consumption; consequently, cysteine supplementation to protein-energy 
malnourished children also led to an increase in erythrocyte GSH synthesis 
(Badaloo et al. 2002). 
It seems that even suboptimal, not insufficient, protein intake may decrease GSH 
synthesis in experimental animals (Stipanuk et al. 1992) and in humans. Healthy 
adults consuming the minimal amount of protein that is considered sufficient (0.75 
g/kg/d for adults) had decreased erythrocyte GSH synthesis rates, preasumably 
following insufficient cysteine intake (Jackson et al. 2004). Interestingly, however, 
septic paediatric patients on limited nutritional support had decreased whole 
blood glutathione synthesis rates despite high plasma cysteine concentration and 
flux (Lyons et al. 2001). It seems that decreased GSH synthesis rates and/ or low 
GSH levels may occur in various forms of critical illness even in the absence of 
actual protein-energy malnourishment, presumably following a catabolic state that 
disfavours synthetic processes. 
The findings about the possible deficiency in GSH precursors and/ or GSH 
synthetic capacity in various disease states and stress situations has led to reflections 
about whether the current recommendations for nutritional sulphur amino acid 
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intake should be revised (Tesseraud et al. 2008). However, excess cysteine must 
be avoided, as high levels are toxic (Stipanuk et al. 2006).
Additionally, it has been shown that nutrition (diet and fasting) not only influence 
thiol levels, but also thiol redox state.  Cysteine and GSH redox states in human 
plasma, probably reflecting the situation in less accessible tissues, are more oxidised 
during fasting, becoming more reduced after meals (Blanco et al. 2007). Sulphur 
amino acid (methionine and cysteine) intake is shown to influence plasma thiol 
redox states with a more reducing state prevailing during high sulphur amino acid 
intake and vice versa (Jones et al. 2011, Park et al. 2010).
5.5.3.2. Decreased thiol antioxidant supplies in some inherited metabolic diseases
Organic acidaemias
Even if oxidative stress has often been suggested to play a role in the (neuro)
pathogenesis of organic acidaemias (Wajner et al. 2004), little is known about the 
function of antioxidant systems in these diseases. Recently, it has been speculated 
that organic acids, such as MMA, may impair mitochondrial glutathione transport 
due to an inhibitory effect of dicarboxylic acids to the transporter (Morath et al. 
2008), as it is known that organic acids inhibit the mitochondrial dicarboxylate 
carrier (Mirandola et al. 2008). Defects in mitochondrial GSH transport could 
have major consequences, as mitochondria are unable to synthesize GSH; their 
antioxidant defences are dependent on GSH transport by the dicarboxylate and 
the 2-oxoglutarate carriers (Lash 2006). It has also been shown that mitochondrial 
GSH status is critical for mitochondrial function an influences mitochondrial 
ROS production, which participates to regulation of cell viability and signalling 
(Fernandez-Checa et al. 1998; Lash 2009).
Moreover, more evidence form deficient antioxidant supplies in organic acidaemias 
comes from several in vitro studies that report a positive response to antioxidant 
administration following exposure to organic acids, expressed as improvement of cell 
survival (McLaughlin et al. 1998) or reduced neurological defects in experimental 
animals (Fighera et al. 1999, Pettenuzzo et al. 2002). There is also a case report about 
a positive response to antioxidant therapy in a patient with a severe metabolic crisis 
of methylmalonic acidaemia (Treacy et al. 1996), but patient studies are lacking.
Following the role of GSH as a detoxifier in conjugation reactions, it is interesting 
to speculate whether GSH could be depleted due to extensive conjugation reactions 
in organic acidaemias. Organic acids may accumulate to a thousandfold normal 
levels, and as wide array of chemical compounds are excreted as GSH conjugates. 
Under such exceptional metabolic circumstances GSH depletion due to a massively 
increased use in conjugation reactions could occur. However, it has not been studied 
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whether organic acids are included in the possible substrates for GST-catalysed 
reactions (Ballatori et al. 2009 a).
Hypoglycaemia
Cells need energy to produce GSH and maintain antioxidant capacity, and glucose is 
the preferred substrate for energy metabolism in most tissues. Glucose is also needed 
for NADPH production and NADPH, in turn, provides the reducing power for GR 
to regenerate GSH from GSSG. Thus it is reasonable to assume that antioxidant 
systems could be compromised during hypoglycaemia. There is, nevertheless, only 
limited information about the function of thiols and other antioxidant systems 
during hypoglycaemia, and results are partly contradictory.
According to some studies, glucose deprivation in vitro leads to a decrease 
in GSH (Li et al. 1998, Singh et al. 2004), and in experimental animals, plasma 
oxidised to reduced glutathione ratio (GSH/GSSG) decreases following insulin-
induced hypoglycaemia (Jiang and Sato 1999). However, in an in vitro study on 
thiol levels in glucose-deprived erythrocytes (Coleman et al. 2007), total thiol levels 
did not change during glucose deprivation despite the presence of methaemoglobin 
as a sign of oxidative stress. Moreover, when the glucose-deprived cells were treated 
with the antioxidant lipoic acid, thiol levels actually decreased.
Studies, especially in vivo, about the function of antioxidant systems during 
hypoglycaemia are scarce. In two studies focusing on the effects of hyperinsulinaemia 
to oxidative stress markers in healthy human subjects, whole-blood GPx activity 
(and erythrocyte superoxide dismutase activity) decreased during insulin-induced 
hypoglycaemia (Koska et al. 1997, Koska et al. 2000). The authors do not discuss 
the significance of these findings and the possible association of hypoglycaemia to 
compromised antioxidant activity.
Mitochondrial diseases
ATP energy is needed for the maintenance and function of antioxidant systems, 
including GSH synthesis and transport to mitochondria, and impairment of energy 
metabolism may well influence antioxidant supplies. Accordingly, patients with 
defects in the function of the electron transport chain had decreased tissue GSH 
levels (Hargreaves et al. 2005). Moreover, poor antioxidant capacity has been shown 
to further compromise mitochondrial function (Bolanos et al. 1996, Hargreaves et 
al. 2005). Especially the redox status of thiols is critical for mitochondrial function 
(Lash 2006); mitochondrial GSH status regulates mitochondrial function and ROS 
production (Fernandez-Checa et al. 1998, Lash 2009).
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However, the redox state and metabolism of thiols in diseases with compromised 
mitochondrial function have not been studied in detail, and the existing studies 
have led to conflicting results. In cultured human fibroblasts derived from patients 
with Complex I deficiency (Verkaart et al. 2007) no changes in thiol redox status 
were observed, whereas in patients with Friedreich’s ataxia (Piemonte et al. 2001), 
blood glutathione redox status shifted towards increased oxidation, which was also 
observed in a yeast model of Friedreich’s ataxia in addition to decreased intracellular 
glutathione levels (Auchère et al. 2008).
5.5.4. THIOL THERAPY: INCREASING THIOL LEVELS
As low GSH levels, both in plasma and in other tissues, are associated with a wide 
variety of disease states, it is a reasonable approach to try to increase blood and, 
ultimately, tissue GSH levels.  However, GSH cannot be supplemented by itself, as it 
is a hydrophobic (unsoluble) molecule. Even if mechanisms for GSH uptake exist in 
some cells, they are not significant under physiologic conditions  (Lash 2009, Ballatori 
et al. 2009 a); in addition, GSH is very short-lived (less than 3 minutes) in human 
plasma (Wendel and Cikryt 1980).  Thus, attempts have been made to develop GSH 
derivatives with increased solubility or products enhancing GSH synthesis.
5.5.4.1. Glutathione esters and other glutathione derivatives
GSH ester prodrugs acting as soluble GSH transport vehicles include GSH 
monomethyl-, monoethyl-, diethyl- and isopropyl esters (Cacciatore et al. 2010). 
GSH esters bypass the ATP-requiring enzymatic steps required for GSH synthesis 
from its precursors, and are independent of the negative feedback that GSH exerts 
to GCS. GSH esters are also able to penetrate mitochondrial GSH pool. 
GSH derivatives with modified cysteinyl moiety have also been developed. 
S-acetyl-GSH, S-phenylacetyl-GSH and L-cysteine-glutathione mixed disulphide 
are more stable and soluble than GSH and increase reduced intracellular 
sulphydryl groups, providing both GSH and cysteine to the cell (Cacciatore et 
al. 2010).
However, in vivo evidence is on GSH derivatives is scarce, not to mention clinical 
studies. As GSH has complex interorgan transport and homeostasis mechanisms, 
results from studies on GSH uptake by cultured cells are not directly adaptable to 
the whole human organism.
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Table 5. Mechanisms underlying increased free radical production or compromised antioxidant function 
during several metabolic problems (reviewed in chapters 5.3.6. and 5.5.3.).
Studies with negative results are not represented in the table but are reviewed in the text.
References are marked with a superscript number in the table and listed in numeric order under 
the table.
Disorder Increase in ROS production; 
Possible mechanism favouring ROS 
production




“Leakage” of ROS from defective 
ETC 1, 2:  increased
•	 hydroxyl radical 3 
•	 superoxide 4, 5 
•	 hydrogen peroxide 5 production in 
	 cultured fibroblasts from patients with 
	 Complex I deficiency.
Decreased muscle GSH in 
patients with ETC defects 17
Oxidation of blood GSH in 
patients with Friedreich’s ataxia 18 
Oxidation of GSH and 
decreased GSH in a yeast 
model of Friedreich’s ataxia 19 
Organic 
acidaemias 
PA and MMA inhibit mitochondrial 
energy production 6, 7, 8, 9, 10; mitochondrial 
dysfunction leads to ROS production as 
described above.
PA and MMA inhibit membrane 
Na+K+ATPase 9, 11, 12 increasing free 
intracellular calcium and ROS production 
MMA may impair mitochondrial 
glutathione transport 20 
Possible loss of GSH in 
conjugation reactions following 
accumulation of organic acids 
(not studied).
Hypoglycaemia Increased hydrogen peroxide 13 and 
superoxide 13, 14 production in brain tissue 
of experimental animals following insulin-
induced hypoglycaemia. 
Release of nitric oxide in brain tissue of 
experimental animals following insulin-
induced hypoglycaemia 15 
Activation of NADPH oxidase, leading to 
superoxide production following glucose 
deprivation in cultured cortical neurons 14 
Increased intracellular and mitochondrial 
superoxide, hydrogen peroxide and 
peroxynitrite in cultured retinal cells with 
glycolysis inhibition 16 
Glucose deprivation in vitro 
leads to a decrease in GSH 21, 22    
Plasma GSH/GSSG ratio 
decreases in insulin-induced 
hypoglycaemia in experimental 
animals 23 
GSH depletion in cultured 
retinal pericytes following 
glucose reduction 21 
Vitamin E prevented cellular 
injury induced by glycolysis 
inhibition in cultured retinal 
cells 15 
1 Wallace 1999; 2 Chen 2003; 3 Luo et al. 1997; 4 Pitkänen and Robinson 1996; 5 Wani et al. 2008; 
6 Stumpf et al. 1980; 7 Nakai et al. 1991; 8 Dutra et al. 1993; 9 McLaughlin et al. 1998; 10 Okun et al. 
2002; 11 Wyse et al. 1998; 12 Wyse et al. 2000; 13 McGowan et al. 2006; 14 Suh et al. 2007; 15 Suh et al. 
2008; 16 Rego et al. 1999; 17 Hargreaves et al. 2005; 18 Piemonte et al. 2001; 19 Auchère et al. 2008; 20 
Morath et al. 2008); 21 Li et al. 1998; 22 Singh et al. 2004; 23 Jiang and Sato 1999
5.5.4.2. N-Acetylcysteine and other cysteine prodrugs
Under most circumstances, cysteine is the limiting component of GSH synthesis 
and thus the most logical approach would be to supplement cysteine. This approach 
naturally requires that the ability of cells to synthesise GSH form its precursors is 
not affected. Glycine and glutamate, also needed for GSH synthesis, are generally 
found in abundance compared to cysteine, and are thus not efficient for promoting 
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GSH synthesis.  Cysteine is unstable and and its therapeutic window is narrow 
(Taylor et al. 1992); it is easily oxidised to cystine, which is toxic due to low solubility 
in neutral pH. Thus, several cysteine prodrugs including L-2-Oxothialzolidine-4-
carboxylate (OTC) (Taylor 1992) and N-Acetylcysteine (deVries 1993) have been 
developed. N-Acetylcysteine (NAC) is in clinical use, which is, however, limited, due 
to its suboptimal pharmacologic properties (Cacciatore et al. 2010). 
5.5.4.3. Lipoic acid 
a-lipoic acid (1,2-dithiolane-3-pentanoic acid, or thioctic acid) is a dithiol compound 
synthesised from octanoic acid in mitochondria, where it participates to energy 
metabolism by acting as a cofactor for a-ketoacid dehydrogenases. Beyond this role, 
lipoic acid seems to serve multiple purposes: it is a potent antioxidant, a detoxifier, 
and a modulator of inflammatory response. Lipoic acid has been used in clinical 
practice for treatment of diabetic retinopathy and neuropathy. Its safety in moderate 
doses has been demonstrated in several clinical trials, reviewed by Shay et al. 2009, 
although some questions over optimal dosage and safety in large doses remain.
As a thiol antioxidant, lipoic acid participates to maintenance and regulation of 
thiol redox status and thiol levels, and it is able to increase intracellular GSH levels 
(Bast 1988, Shay et al. 2009, Suh et al. 2004). Lipoic acid seems to increase cysteine 
availability by reducing cystine to cysteine, enhancing its uptake by cells; in addition, 
lipoic acid induces GSH synthesis by influencing redox-regulated signalling cascades 
and activating Nrf2-dependent transcription of antioxidant response element (ARE) 
–genes (Suh et al. 2004, Shay et al. 2009).
This far, several candidates for increasing intracellular thiols exist; lipoic acid is 
perhaps the most promising agent. Still, evidence from clinical studies is needed to 
evaluate the possibilities lipoic acid and other thol agents may offer for treatment 
– and whether increasing thiol levels truly offers therapeutic potential.
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6. OBJECTIVES OF THE STUDY
This series of studies has two objectives, both dealing with biochemical changes in 
situations where metabolic perturbations occur. These changes are seen as metabolic 
markers of the underlying pathogenetic processes, offering new insights into disease 
mechanisms. 
(1) To study thiol metabolism in patients with different inborn 
errors of metabolism (organic acidaemias, hypoglycaemic episodes, 
mitochondrial diseases, homocystinuria) and in cell culture models, where 
similar metabolic conditions are created. 
   
 Thiol homeostasis and thiol redox status, serving multiple metabolic and 
regulatory purposes, might be affected in inborn errors of metabolism 
following increased oxidative stress and nutritional factors. The changes 
in thiol status could have a role in the development of complications in 
these diseases. If confirmed, these changes in thiol metabolism would 
provide new understanding on the pathogenesis of different inborn errors 
of metabolism and even offer therapeutic potential.
(2) To investigate the metabolic disturbances in patients with cow’s 
milk allergy (CMA) as a potential new diagnostic tool.
  
 The composition and the metabolic activity of intestinal flora, which can 
be regarded as a tissue with substantial metabolic activity, are altered 
in patients with CMA or other food allergies. In addition, intestinal 
permeability to microbial products may be increased. This could lead to 
metabolic changes in the host. If measurable changes are present, these 
could be investigated for diagnostic purposes and as markers of metabolic 
effects of inappropriate nutrition.
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7. MATERIALS AND METHODS
7.1. HUMAN SAMPLES
7.1.1. PATIENTS WITH INBORN ERRORS OF METABOLISM OR SUSPECTED  
 HYPOGLYCAEMIA
17 children with suspected hypoglycaemic episodes, 10 children with a diagnosis 
of mitochondrial disease, 11 children with methylmalonic, propionic or isovaleric 
acidaemia and 6 children with homocystinuria attending the metabolic outpatient 
clinic in Great Ormond Street Hospital, London, UK, were enrolled in 1999-2000. 
The characteristics of the patients are summarised in Table 6 and presented in 
more detail in the original publications I, II and III.
Among the patients with mitochondrial diseases, nine of the ten children had 
confirmed deficiencies of one or more of respiratory chain enzyme complexes I, 
II+III and IV, in skeletal muscle and/or fibroblasts. Four (40%) had a genetic 
diagnosis, including three with mitochondrial DNA mutations and one with a 
homozygous SURF1 mutation. 
The patients with organic acidaemias were supervised by a metabolic dietitian 
and received individually tailored treatment including carnitine, glycine (IVA only), 
metronidazole, vitamin supplements etc, and some had additional medication 
because of renal problems or epilepsy. None of them was severely protein restricted. 
The body mass index standard deviation scores (BMI SDS) were calculated 
using the British 1990 growth reference (Cole 1995). 
7.1.2. CONTROLS FOR PATIENTS WITH ORGANIC ACIDAEMIAS, MITOCHON  
 DRIAL DISEASES AND HOMOCYSTINURIA
Reference data for comparison of values in patients with mitochondrial diseases, 
organic acidaemias and homocystinuria were derived from children referred to 
the same clinic for suspicion of hypoglycaemia caused by metabolic disease. These 
children were then found to be well, and no metabolic or any other disturbance 
could be identified after thorough clinical and laboratory investigation including a 
diagnostic fast (Table 6.). 
62





Mitochondrial disease 10 3-14 4/6
Organic acidaemia 11 1-16 8/3
isovaleric acidaemia 2 1.3-6.4 0/2
methylmalonic acidaemia 7 3.4-16 5/2
propionic acidaemia 2 5.7-12.2 2/0
Suspected hypoglycaemia 17 0.5-10.7 12/5
When fasted, plasma glucose below 3.0 mmol/l in 7 1.7-10.7 4/3
Homocystinuria 6 1-11 4/2
CONTROL 6 2.2-6 4/2
7.1.3. PATIENTS WITH SUSPECTED CMA
Patients in this study were a randomly selected subset (n=35) of a larger study cohort 
(n=230) that was studied between 1999 and 2002 in the Skin and Allergy Hospital 
in Helsinki University Central Hospital, Helsinki, Finland (Viljanen et al. 2005).
Children under 12 months of age with symptoms suggestive of CMA, atopic 
eczema being the obligatory symptom, and having received no probiotic treatment 
for 6 weeks before the study were enrolled. 
7.1.4. ETHICAL ASPECTS
7.1.4.1. Patients with inborn errors of metabolism and suspected hypoglycaemia
In patients with mitochondrial diseases, organic acidaemias and homocystinuria, the 
blood samples for this study were taken under a routine follow-up visit at the same 
time than other blood samples for clinical purposes. For patients with suspected 
hypoglycaemic episodes, the samples were taken before and after a diagnostic fast 
with other blood samples included in the fasting protocol. 
When appropriate, the children gave informed consent to participate to the study. 
When the child’s age or condition prevented this, informed consent was obtained 
from the child’s parents or guardians. The research ethics committee of GOSH/
Institute of Child Health, University of London, approved the study.
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7.1.4.2. Patients with suspected CMA
The local ethics committee approved the study protocol and informed consent was 
obtained from one parent of each participating infant.
One parent of each infant gave informed consent to participate to the study. The 
urine samples from the patients with suspected CMA were taken under the follow-
up visits needed for the exclusion or confirmation of CMA. The Ethics Committee of 
the Skin and Allergy Hospital of the Helsinki University Central Hospital approved 
the study protocol.
7.1.5. SPECIFIC STUDY PROTOCOLS
7.1.5.1. Fasting protocol for investigation of suspected hypoglycaemia
The maximum duration of the fast, ranging from 8 to 24 hours, was determined 
from the history and the age of the child. The fast was discontinuated before the 
planned time if the child developed clear neuroglycopaenic symptoms. An indwelling 
cannula was placed to collect the blood samples and to give intravenous glucose 
if necessary. 
During the fast, blood glucose was measured hourly and the child’s clinical 
condition was watched carefully to identify hypoglycaemia without delay. 
A blood sample was taken both after a normal feeding interval (1st sample) and 
after the total duration of the fast (2nd sample).
7.1.5.2. Probiotic administration and CMA diagnosis
The study protocol is explained in detail in (Viljanen et al. 2005) and briefly 
summarised in Figure 5. 
The infants with suspected CMA were first assessed for the severity of atopic 
eczema by the Severity Scoring of Atopic Dermatitis (SCORAD). Skin prick 
tests (SPT) for several relevant allergens including CM and serum specific IgE 
concentrations for cow’s milk and wheat were examined, and a urine sample was 
taken (1st visit).  Infants were then randomised by a computer-generated block 
randomisation in blocks of 6 infants to receive either Lactobacillus rhamnosus 
GG (LGG) or placebo in a double-blind trial for 4 weeks, after which they were 
examined again, and a new urine sample was taken (2nd visit). 
Prior to the 1st visit, all the infants in both groups had been continuously 
exposed to cow’s milk in some form (either directly from the infant’s or indirectly 
from the mother’s diet).  Only after the 1st visit, cow’s milk was eliminated 
from the infants’ and their breast-feeding mothers’ diets for eight weeks; 
an extensively hydrolysed whey formula was given instead. For those with 
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a favourable response to elimination diet, a double-blind placebo-controlled 
cow’s milk challenge was then performed to confirm or exclude the diagnosis 
of milk allergy. 
After confirmation or exclusion of CMA, urine samples of 16 infants with positive 
double-blind placebo-controlled food challenge (DBPCFC) and SPT to CM (CMA 
group) and 19 infants with a negative challenge and with no detectable allergies or 
sensitisations to any of the studied allergens (eczema only group) except for one 
egg-sensitized child with no egg introduced in the diet) were randomly selected for 
analysis. For the patients with CMA, urine samples both before and after LGG or 
placebo treatment were analyzed. 
Figure 5. Study protocol (IV)
CM elimination started only after the first visit. Urinary organic acids were studied before and after 
LGG or placebo treatment in 35 infants. At the time of the first analysis, the children were exposed 
to CM, and at second analysis, CM had been eliminated and LGG or placebo administered.
The analyses were blinded to the patients’ condition, as the diagnosis was made only after the 
DBPCFC several weeks later.
DBPCFC = double-blind placebo-controlled food challenge
7.1.6. BLOOD SAMPLES FROM PATIENTS WITH INBORN ERRORS OF   
 METABOLISM AND THEIR CONTROLS
A blood sample was taken after informed consent during a routine follow-up 
visit to the clinic or, in patients with suspected hypoglycaemia, before and 
after the diagnostic fast. To control for the possible influence of fasting and 
diurnal variation to plasma thiols, all samples were taken after an overnight 
fast. The sample was kept on ice and centrifuged within 15 min to separate 
plasma from erythrocytes.
The erythrocyte pellet was frozen at –80°C, plasma was frozen as such and after 
protein precipitation with sulphosalicylic acid. 
For analysis, erythrocytes were haemolysed with distilled and purified water.
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7.1.7. URINARY ORGANIC ACID ANALYSIS IN PATIENTS WITH AND   
 WITHOUT CMA
All urine during 5 hours was collected in an adhesive urine bag, cooled immediately 
to +4 o C, and stored at -20 o C. During the first 2 hours of the collection, infants 
were allowed nothing by mouth.
For gas chromatography/mass spectrometry analysis, urine samples were 
thawn. A special dip-stick (Dip ´N Dry, US BioTek, Seattle, WA, USA) was dipped 
in the urine and dried according to manufacturer’s instructions. Creatinine was 
measured in addition to 37 stable easily identified stable organic acids (adipate, 
a-hydroxybutyrate, a-keto-b-methyvalerate, a-ketoglutarate, a-ketoisocaproate, 
a-ketoisovalerate, benzoate, b-hydroxybutyrate, citrate, cis-aconitate, ethylmalonate, 
fumarate, hippurate, homovanillate, hydroxymethylglutarate, isocitrate, 
kynurenate, lactate, malate, methylmalonate, orotate, para-hydroxyphenyllactate, 
pyroglutamate, pyruvate, quinolenate, suberate, succinate, tartarate, tricarbyllate, 
vanilmandelate, 2-hydroxyphenyllactate, 2-indoleacetate, 5-hydroxyindoleacetate). 
All acid concentrations were normalized to creatinine level. The assays were done 
blinded to the patient data. 
7.2. CULTURED CELLS
7.2.1. HUMAN FIBROBLASTS EXPOSED TO ORGANIC ACIDS
Human fibroblasts from healthy volunteers were obtained with normal procedure 
and cultured in 37 o C and 5% CO2. The medium was RPMI 1640 with 10% foetal 
bovine serum and 2% streptomycin-penicillin. The medium was changed every 
two days. The cells were grown on 6-well plates to confluence and incubated with 
propionic acid (50 μM; 0.5 mM; 5 mM), methylmalonic acid (10 μM, 0.1 mM; 1mM) 
or isovaleric acid (10 μM; 0.1mM; 1mM) for 24 hours (2 wells for each incubation), 
after which a sample was taken of the media and cells were washed and harvested. 
The samples were stored in -80°C until analysis. 
7.2.2. GLUCOSE-DEPRIVED HEPG2 CELLS (HUMAN HEPATOBLASTOMA CELLS)
The cells were grown on 6-well plates in DMEM, which had either normal glucose, 
half of normal glucose or no glucose for 28 h (12 wells for each), after which a 
sample was taken of the media and cells were washed and harvested. The samples 
were stored in -80 C until analyis. 
66
7.2.3. GLUCOSE-DEPRIVED 293T CELLS (TRANSFORMED HUMAN EMBRYONIC  
 KIDNEY CELLS)
The cells were grown, harvested and stored otherwise as HEPG2 cells, but samples 
were taken at 24 h and 48 for each glucose concentration (4 wells for each).
7.3. THIOL ANALYSIS
7.3.1. PLASMA THIOLS
The concentrations of glutathione and cysteine with (corresponding to total) and 
without (reduced thiols only) dithiotreitol (DTT) were measured by HPLC in the 
plasma samples with previously described methods (Ahola et al. 2004). In short, 
sulphydryls were derivatised with monobromobimane. A reversed-phase C-18 
column was used to separate the adducts and quantitation was performed using 
a fluorescence detector. 
7.3.2. ERYTHROCYTE THIOLS
In haemolysed erythrocytes, only total glutathione and cysteine were measured 
by the HPLC-based method described above, as haemolysis increases the oxidized 
fraction unpredictably. The glutathione and cysteine concentrations in haemolysed 
erythrocytes were normalised to the protein content of the samples.
7.3.3. THIOLS IN CULTURED CELLS
The concentrations of glutathione and cysteine with (corresponding to total) and 
without (reduced thiols only) dithiotreitol (DTT) were measured by HPLC in the 
cultured fibroblasts as previously described for plasma thiols (7.3.1).
7.4. ERYTHROCYTE ENZYME ACTIVITIES
GPx, GR, GST and G6PDH activities were measured in the haemolysed 
erythrocytes with a spectrophotometric assay as described earlier (Ahola et al. 
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2004). The assay detects the speed of formation of NADPH, which is measured 
spectrophotometrically using 340 nm as wavelength (the absorption maximum 
of NADPH).
Glucose 6-phosphate and NADPH were purchased from Boehringer Mannheim 
GmBH, NADP from Roche and all other chemicals from Sigma. Protein concentration 
was determined with the Bio-Rad kit. 
All measurements were done in duplicate, and the mean value was calculated 
and normalised to erythrocyte protein content. In addition, also the absorbances 
of plain reagents and plain sample (without reagents) were controlled to check for 
possible iatrogenous enzyme activity.
The enzyme activity assays are explained in detail below.
7.4.1. GLUTATHIONE PEROXIDASE 
The activity of GPx was determined in 0.10 M potassium phosphate buffer (pH 
7.0) with 1.00 mM EDTA, 0.09 mM NADPH, 0.17 mM GSH, 10 mM tert-butyl-
hydroperoxide and 23 IU GR.  
7.4.2. GLUTATHIONE REDUCTASE
GR, the enzyme activity was measured in 0.10 M potassium phosphate buffer (pH 
7.0) with 1.00 mM EDTA, 0.09 mM NADPH and 1.00 mM GSSG. 
7.4.3. GLUCOSE 6-PHOSPHATE DEHYDROGENASE
The activity of G6PDH was determined in 0.10 M potassium phosphate buffer (pH 
8.0) with 1.00 mM NADP, 1.00 mM glucose-6-phosphate and 0.50 mM dithiotreitol. 
7.4.4. GLUTATHIONE TRANSFERASE
The assay was performed with 0.85 mM 1-chloro-2,4-dibenzene in 0.10 mM 
potassium phosphate buffer (pH 6.5) with 1.50 mM GSH. 
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7.5. OXIDATIVE DAMAGE TO ERYTHROCYTE LIPIDS AND 
 PROTEINS
Oxidative damage to erythrocyte lipids and proteins was measured by determining 
the concentrations of a thiobarbituric acid –reactive species, malondialdehyde 
(MDA) and carbonylated proteins, respectively. 
MDA concentration was measured in a thiobarbituric acid  (TBA)–based 
spectrophotometric assay, described by Draper in 1993 and outlined below. 
Protein carbonyls were determined spectrophotometrically in the presence of 
2,4-dinitrophenylhydrazine as published by Levine in 1994 and described below.
7.5.1. THIOBARBITURIC ACID –REACTIVE SUBSTANCES (TBA-RS)
For the measurement of TBA-RS, a reagent consisting of 0.67% thiobarbituric 
acid and acetic acid (1:1) was prepared. A mixture containing hemolysed red cells, 
water, the reagent and 1.22 M phosphoric acid (volumes 1:9:5:5, respectively) was 
incubated for 60 minutes in 95 C. After incubation, the absorbances of the samples 
were measured spectrophotometrically, using 532 nm as wavelength. To calculate 
the MDA levels from the measured absorbance, 1.54 x 105 x l/(M x cm) was used 
as MDA absorption coefficient.
7.5.2. PROTEIN CARBONYLS
To determine the amount of carbonylated proteins, 20% trichloroacetic acid 
(TCA) was added to the samples to precipitate the proteins. These were then let 
react with 10 mM 2,4-dinitrophenylhydrazine for 60 minutes (1 mg of protein 
and 500 ml of 2,4-DNPH). The reaction was stopped with 20% TCA and the 
sediment was washed three times with mixed ethanol and ethylacetate (1:1). 6M 
guanidine was added to the sediment and, after incubation for 15 minutes in 
37 C, the absorbance of the supernatant was measured spectrophotometrically 
(wavelength 365 nm). 
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7.6. STATISTICAL ANALYSIS
7.6.1. COMPARISON OF PATIENTS WITH ORGANIC ACIDAEMIAS,   
 MITOCHONDRIAL DISEASES AND HOMOCYSTINURIA TO CONTROLS
As the data was not normally distributed, statistical significance of measured 
parameters was tested by two-sided nonparametric Mann-Whitney U-test. Two-
sided exact p was calculated with Statistica 7 software, and values < 0.05 were 
considered statistically significant. 
7.6.2. ANALYSIS OF THIOL LEVELS BEFORE AND AFTER FASTING IN PATIENTS  
 WITH SUSPECTED HYPOGLYCAEMIA
The concentrations of plasma thiols at the end of the fast (2nd sample) were compared 
to the concomitant plasma glucose value, and Pearson’s correlation coefficient (R) 
was calculated.
The patients were divided in hypoglycaemic (plasma glucose below 3.0 mmol/l 
the end of the fast) and normoglycaemic (the rest) groups. The use of this particular 
value as a cut-off limit may be argued; this is discussed in detail in section 5.1.2.
The changes (expressed as the arithmetical difference) in erythrocyte thiol 
concentrations from the 1st sample to the 2nd sample were compared between 
the hypoglycaemic and normoglycaemic groups by unpaired t-test. A two-tailed 
probability (p) < 0.05 was considered statistically significant. 
In addition, the statistical significance of the relative proportions of changes to 
opposite directions in erythrocyte thiol levels in these two patient groups was tested 
with Statistica 7 software, and p values < 0.05 were considered statistically significant.
7.6.3. COMPARISON OF URINARY ORGANIC ACIDS IN PATIENTS WITH AND  
 WITHOUT CMA AND BEFORE AND AFTER LGG TREATMENT
Normal distribution of data was assured by logarithmic conversion of the measured 
values, and the mean, standard deviation and median were calculated for each 
subgroup. To evaluate the effects of LGG treatment, the difference in urinary organic 
acid concentrations following administration of either placebo or LGG was calculated. 
Statistical significance between the patients with and without CMA and before 
and after treatment was tested by two-tailed unpaired t-test and p<0.05 was 




8.1. THIOLS IN PATIENTS WITH INBORN ERRORS OF METABOLISM
Basic information (including diagnosis, age, sex, height, weight and clinical condition 
at time of blood sampling) was available from nearly all patients and all controls. 
The height and weight of three patients with hypoglycaemia were missing. One 
patient with mitochondrial disease was unable to stand, and the height had not 
been measured.
All plasma samples from participating patients were included for thiol analysis 
except for one patient with isovaleric acidaemia, whose plasma as well as erythrocyte 
samples were unavailable at the time of analysis. This patient, having no data to 
analyse, was excluded from the study. One patient with homocystinuria was studied 
twice, having an acute respiratory infection during the first visit. Only the blood 
sample from the second visit was used for data analysis, as also all other patients 
were studied during routine control visits without any acute problems.
Due to a small number of patients and controls, the variation in all measured 
thiols was wide in patients and in controls. The data was not normally distributed.
All values represent mean ± standard deviation (SD) unless otherwise stated. p 
values are derived from several different statistical tests according to the data and 
hypotheses that are tested, as is explained in 7.6.
8.1.1. PLASMA THIOLS AND THEIR REDOX STATE
Both free (reduced) and total glutathione and cysteine in plasma were measured. 
Total cysteine comprises free (i.e. reduced) cysteine, cystine (i.e. the oxidised 
disulphide form), and protein-bound (i.e. oxidised) cysteine. Total glutathione 
comprises free (i.e. reduced) glutathione, glutathione disulphide (i.e. the oxidised 
disulphide form), and protein-bound (i.e. oxidised) glutathione.
The redox state is here assessed as CYSH/CYSS ratio, GSH/GSSG ratio or by 
comparing plasma thiols before and after plasma protein precipitation. True redox 
potentials have not been calculated.
The analysis of plasma thiols before and after protein precipitation allows 
estimation of the amount of protein-bound glutathione or cysteine, which is always 
oxidised. If a greater fraction of plasma total glutathione or cysteine is protein-
bound, then the plasma glutathione or cysteine pool is more oxidised.
Patients with organic acidaemias, hypoglycaemia, mitochondrial diseases and 
homocystinuria had altered levels of plasma thiols as compared to controls. Their 
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plasma thiol redox status was indicative of oxidative stress even in the absence of 
acute critical illness. 
8.1.1.1. Plasma cysteine 
Cysteine is the most important non-protein thiol in plasma. In this series of studies, 
all studied inherited metabolic diseases were associated with lower levels of plasma 
free cysteine and, hence, a more oxidised plasma cysteine redox state. 
Plasma cysteine in patients with mitochondrial diseases
Patients with mitochondrial diseases had significantly lower levels of reduced 
cysteine in plasma than controls (12.7 ± 2.7 mmol/l vs. 19.5 ± 5.6 mmol/l, p = 
0.008; Figure 6), whereas their total plasma cysteine levels did not differ. Thus, 
the reduced to total cysteine ratio in plasma of patients with mitochondrial diseases 
was significantly decreased (0.063 ± 0.026 vs. 0.097 ± 0.021, p = 0.023; II).
Plasma cysteine in patients with organic acidaemias
Total plasma cysteine levels were similar or slightly higher in patients with organic 
acidaemias as compared to controls (245.7 ± 32.9 mmol/l vs. 218.1 ± 26.6 mmol/l; 
Figure 6), but the concentration of free (reduced) cysteine, CYSH, was lower in 
patients than in controls (III). Consequently, the ratio of reduced to oxidised cysteine 
(CYSH/CYSS) was lower in the plasma of the patients with organic acidaemias. 
Plasma cysteine in hypoglycaemic patients
Following fasting, the levels of reduced cysteine in untreated plasma correlated 
significantly to the blood glucose level (R=0.63, p<0.02), suggesting that a decrease 
in blood glucose is associated with a decrease in reduced cysteine in plasma (I).
Plasma glucose was not correlated to levels of oxidised cysteine (CYSS) or to 
levels of total cysteine in plasma.
Plasma cysteine in patients with homocystinuria (unpublished data)
Total plasma cysteine levels were significantly lower both in untreated and in acid-
treated plasma of patients with homocystinuria as compared to controls (170.4 ± 
34.8 vs. 218.1 ± 26.6 mmol/l, p = 0.026; and 102.1 ± 28.5 vs. 181.8 ± 82.1 mmol/l, p 
= 0.041, respectively; Figure 6). The levels of free cysteine were lower in patients 
but did not differ significantly between patients and controls, making the CYSH/
CYSS ratios similar (0.099 ± 0.03 vs. 0.097 ± 0.02). However, patients with 
homocystinuria tended to have more protein-bound (oxidised) plasma cysteine 
than controls, but the variation was wide (the ratio of protein-bound cysteine to 
total plasma cysteine was 0.40 ± 0.10 vs. 0.14 ± 0.47 in patients and controls, 
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respectively). This suggests, albeit indirectly, that the patients’ plasma cysteine pool 
was more oxidised in a similar way than that of patients with organic acidaemias, 
mitochondrial diseases and hypoglycaemia. 
Figure 6. Plasma free = reduced cysteine (CYSH; Mean + SD) in patients with
OA = (any) organic acidaemia
IVA = isovaleric acidaemia
MMA = methylmalonic acidaemia
PA = propionic acidaemia
HG (1) = hypoglycaemia, 1st sample
HG (2) = hypoglycaemia, 2nd sample (during hypoglycaemia)
MC = mitochondrial diseases
HCys = homocystinuria
Plasma levels of total cysteine did not dier markedly between patients and controls except for 
the patients with homocystinuria with lower plasma total cysteine levels.
8.1.1.2. Plasma glutathione
Plasma free (reduced) glutathione concentrations are very low, in the micromolar 
range. Consequently, in this series of studies, plasma free GSH concentrations were 
often below the detection limit of the analysis. This decreases the power of the study 
to find statistically significant changes in plasma free glutathione levels or plasma 
glutathione redox status. 
To assess the redox state of plasma GSH/GSSG pair when GSH levels were too 
low to be measured, we compared plasma total GSH before and after precipitation 
of plasma proteins as explained in 8.1.1. 
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Figure 7. Total plasma glutathione in patients with
OA = (any) organic acidaemia
IVA = isovaleric acidaemia
MMA = methylmalonic acidaemia
PA = propionic acidaemia
HG 1 = hypoglycaemia, 1st sample
HG 2 = hypoglycaemia, 2nd sample (during hypoglycaemia)
MC = mitochondrial diseases
Hcys = homocystinuria
Black bars represent the protein-bound fraction of total plasma glutathione.
Shaded bars represent the unbound fraction of total plasma glutathione.
Plasma glutathione in patients with mitochondrial diseases
Plasma concentrations of total glutathione (including oxidised glutathione i.e. 
glutathione disulphide, GSSG, and reduced glutathione, GSH) were lower in patients 
with mitochondrial diseases as compared to controls (26.3 mmol/l vs. 48.9 ± 25.7 
mmol/l; p= 0.031; II), and a greater fraction of the patients’ plasma glutathione was 
protein-bound (oxidised, as explained in 8.1.1) (Figure 7).
These two indirect approaches suggest that patients with mitochondrial 
diseases also had lower plasma levels of reduced glutathione. Indeed, the measured 
concentrations of reduced glutathione in plasma were lower in patients with 
mitochondrial diseases, below the detection limit in nearly all patients, whereas most 
control patients had clearly measurable plasma free glutathione concentrations. This 
suggests that had the analysis been more sensitive to very low GSH concentrations, 
patients with mitochondrial would probably have had significantly lower plasma 
free GSH levels. However, in the presence of several results below the detection 
limit, no statistical analysis was possible.
Plasma glutathione in patients with organic acidaemias
There were no statistically significant differences in plasma glutathione levels 
between patients with organic acidaemias and controls. However, patients with 
organic acidaemias had a lower plasma concentration of total glutathione than the 
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control group (32.9 ± 6.9 mmol/l vs. 48.9 ± 25.7 mmol/l; Figure 7; III); patients with 
isovaleric or propionic acidaemia had clearly lower plasma total GSH levels than 
those with methylmalonic acidaemia, but the small number of patients with each 
specific organic acidaemia makes statistically relevant subgroup analyses impossible.
The difference between healthy controls and patients increased when plasma 
samples were treated with acid before analysis. Thus, in patients with organic 
acidaemias, a greater fraction of plasma glutathione was oxidised as mixed 
disulphides with proteins, as explained in 8.1.1. Again, this indirectly suggests that 
they had lower plasma levels of reduced glutathione, difficult to measure directly.
The levels of free GSH in plasma of patients with organic acidaemias were low, 
mostly below the detection limit of the analysis, not allowing reliable comparison 
between patients and controls.
Plasma glutathione in hypoglycaemic patients
Levels of free GSH were low also in patients with hypoglycaemia, and no statistically 
significant differences between patients and controls or correlation of GSH to blood 
glucose could be observed (R = 0.39, N.S; I). Levels of oxidised glutathione (GSSG) 
were not correlated to plasma glucose (R = 0.45, N.S. ), and also total glutathione 
concentrations remained unaffected by plasma glucose (R = 0.44, N.S.). 
Plasma glutathione in patients with homocystinuria (unpublished data)
Patients with homocystinuria had significantly lower plasma levels of total glutathione 
as compared to controls (22.8 ± 4.0 vs. 48.9 ± 25.7, p = 0.015). (Figure 7)
Levels of free GSH in plasma were two low to allow statistical comparison, or 
assessment of plasma glutathione redox state. 
8.1.2. THIOLS IN HAEMOLYSED ERYTHROCYTES
In haemolysed erythrocytes, only total thiols (i.e. oxidised + reduced thiols) were 
measured.
In patients with organic acidaemias and mitochondrial diseases, erythrocyte 
total thiols were similar to the levels in healthy controls (Table 7).
In patients who became hypoglycaemic after fasting, erythrocyte cysteine 
levels were lower before the fast (0.017 ± 0.022 mmol/l vs. 0.039 ± 0.022 mmol/l); 
the fast induced an increase in total cysteine in the haemolysed erythrocytes of 
hypoglycaemic patients (0.017 ± 0.022 mmol/l to 0.045 ± 0.023 mmol/l) (Figure 
8; Table 7). This was not seen in the control patients (p < 0.05 for the change in 
erythrocyte cysteine as compared to the control group). An increase in erythrocyte 
during fasting was seen in only one control patient vs. 5/7 hypoglycaemic patients 
(p < 0.05 for the comparison of the relative proportions of changes to opposite 
76
directions). The increase in erythrocyte cysteine was not reflected in erythrocyte 
glutathione levels, as there was no corresponding change in the patients’ erythrocyte 
total glutathione (7.04 ± 1.50 mmol/l to 7.05 ± 1.32 mmol/l). 





Control 0.039 ± 0.022 6.7 ± 0.56
Mitochondrial diseases 0.041 ± 0.025 6.4 ± 1.1
Organic acidaemias 0.038 ± 0.030 6.6 ± 1.5
Hypoglycaemia (1) 0.017 ± 0.022 7.0 ± 1.5
Hypoglycaemia (2) 0.045 ± 0.023 7.1 ± 1.3
Figure 8. Dierence in erythrocyte total cysteine (left panel) and erythrocyte total glutathione (right panel) 
before and after the diagnostic fast.




8.2. THIOLS IN CULTURED CELLS
8.2.1. THIOLS IN CULTURED HUMAN FIBROBLASTS EXPOSED TO ORGANIC  
 ACIDS (III)
Both reduced and total glutathione concentrations in fibroblasts decreased after 24 h 
exposure to increasing concentrations of isovaleric and propionic acid. When exposed 
to methylmalonic acid, the concentrations of both reduced and total glutathione 
decreased first, but were then increased following exposure to a higher concentration 
of methylmalonic acid (Figure 9). The ratio of reduced glutathione to oxidised 
glutathione decreased following exposure to methylmalonic and propionic acid. 
Figure 9. Reduced (black or shaded bars) and oxidised (open bars) glutathione in cultured human fibroblasts 
exposed to organic acids. Mean + SD is represented (SDs for both total and reduced glutathione).
Similar results – increased thiol oxidation, but not consistent findings with all three 
acids – were obtained with cysteine levels in fibroblasts exposed to organic acids 
(Figure 10). The concentration of reduced cysteine was lower in fibroblasts exposed 
to IVA, MMA and PA as compared to the control level. In addition, the ratio of 
reduced to oxidised cysteine was lower than the control level in fibroblasts exposed 
to the highest levels of the three organic acids.
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In the cell culture media, the concentrations of glutathione or cysteine did not change 
markedly following exposure to organic acids, indicating that no major uptake or 
release of glutathione or cysteine occurred.
Figure 10. Reduced cysteine (CYSH) in cultured human fibroblasts exposed to organic acids. Mean + SD 
is represented.
Levels of reduced cysteine after exposure to 5 mM PA were under the detection limit and are not 
shown.
8.2.2. THIOLS IN CULTURED HEPG2 AND 293T CELLS EXPOSED TO LOW   
 GLUCOSE OR GLUCOSE DEPRIVATION
In cultured HEPG2 cells, 28-hour glucose deprivation lead to 41% loss of free GSH 
and 23% loss of total glutathione, as compared between cells grown in normal 
glucose content and those completely deprived of glucose. The values of cells grown 
in half of normal glucose were intermediate between these two (Figure 11). CYSH 
and total cysteine values did not change markedly during glucose deprivation 
(unpublished data).
On the contrary, in cultured 293T cells, 24-hour glucose deprivation lead to 
an increase in both CYSH (+150%) and GSH levels (+35%); also total cysteine 
and glutathione levels increased (Figure 11). However, when glucose deprivation 
was prolonged to 48 h, both CYSH and GSH and corresponding total thiol levels 
decreased clearly (unpublished data)
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Figure 11. Total glutathione (black bars) and free GSH (shaded bars) in HEPG2 cells (left panel) and 
293T cells (right panel) cultured in (A) DMEM with normal glucose (B) DMEM with half of normal 
glucose (C) DMEM with no glucose. Mean + SD is represented.
8.3. ACTIVITIES OF ENZYMES RELATED TO GLUTATHIONE   
 ANTIOXIDANT AND DETOXIFYING FUNCTION IN   
 HAEMOLYSED ERYTHROCYTES OF PATIENTS WITH   
 INBORN ERRORS OF  METABOLISM
There were no statistically significant differences in GPx, GR, G6PDH or GST 
activities in patients with mitochondrial diseases or organic acidaemias as compared 
to the controls (Table 8; II, III).
The activities of GPx, GR, G6PDH or GST did not change significantly during 
fasting, did not correlate to blood glucose levels and there were no significant 
differences between hypoglycaemic and normoglycaemic patients (Table 8; I).
Table 8. Erythrocyte enzyme activities (I, II, III)
Erythrocyte
GPx activity
103 IU/ mg prot.
GR activity
104 IU/ mg prot.
G6PDH activity
104 IU/ mg prot
GST activity
104 IU/ mg prot
Control 2.1 ± 0.47 4.6 ± 2.2 3.9 ± 1.1 6.0 ± 5.7
Mitochondrial 
diseases 2.0 ± 0.69 5.5 ± 1.9 4.3 ± 0.72 5.3 ± 5.0





1.84 ± 0.80 5.5 ± 1.3 3.0 ± 0.93 4.1 ± 2.2
Hypoglycaemia, 
2nd sample (during 
hypoglycaemia)
1.92 ± 0.62 4.8 ± 0.98 4.2 ± 0.81 4.9 ± 2.9
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8.4. OXIDATIVE DAMAGE TO ERYTHROCYTE PROTEINS AND  
 LIPIDS IN PATIENTS WITH INBORN ERRORS OF  
 METABOLISM
No statistically significant differences in erythrocyte MDA or protein carbonyl levels 
were noticed in patients with any of the studied inborn errors of metabolism (Table 
9; I, II).
However, variations were wide for MDA levels in all patient groups as well as 
controls; with these results and with a small number of patients and controls implying 
a risk for type II error, the reliability of the whole analysis must be questioned. 
Due to technical problems, results for the MDA levels for two of the children in 
the control group were missing, which decreases the statistical power to detect 
differences between patients and controls.
These results (the absence of increased erythrocyte lipid peroxidation despite 
evidence about a more oxidised plasma redox state) thus need to be interpreted 
with much caution. 
Table 9. Oxidative damage to erythrocyte lipids and proteins (I, II)





Control 1.5 ± 1.5 # 0.045 ± 0.011
Mitochondrial diseases 1.8 ± 1.4 0.047 ± 0.011
Organic acidaemias 1.2 ± 1.2 0.049 ± 0.024
Hypoglycaemia, 1st sample
(when normoglycaemic) 0.5 ± 0.5 0.041 ± 0.0064
Hypoglycaemia, 2nd sample
(during hypoglycaemia) 2.0 ± 1.7 0.044 ± 0.0075
8.5. URINARY ORGANIC ACID PROFILE IN PATIENTS WITH   
 COW’S MILK ALLERGY (IV)
Urinary organic acids were analysed from all the 35 participants. 16 of them had 
confirmed CMA, and their urinary organic acid profile was studied again after 
placebo or LGG treatment. This second urinary sample was not available for analysis 
for two of the CMA patients. This did not affect the pre-treatment results, where all 
the 35 samples were available, and did not cause a type I error in the post-treatment 
results, where no clearly significant results were seen. 
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Missing 2 out of 16 samples may have caused a type II error in the analysis of 
urinary organic acids after LGG or placebo treatment. 
The levels of urinary organic acids as such were not normally distributed in this 
small study population. This problem was solved by logarithmic conversion of the 
measured values, and t test could be used to test statistical significances.
8.5.1. DIFFERENCES IN THE BASELINE URINARY EXCRETION OF ORGANIC   
 ACIDS IN PATIENTS WITH CMA COMPARED TO PATIENTS WITH ONLY  
 ATOPIC ECZEMA
Significant differences between CMA and eczema only -patients were noticed in the 
urinary concentrations of b-hydroxybutyrate (p<0.001; IV); adipate and isocitrate 
(p<0.01 for both; IV); homovanillate, suberate, tartarate, 3-indoleacetate and 
5-hydroxyindoleacetate (p<0.05 for all; IV).
CMA patients had always a higher concentration than eczema only -patients 
and the concentrations did not correlate with the SCORAD values (Table 10).
8.5.2. EFFECTS OF PROBIOTIC (LGG) TREATMENT TO URINARY ORGANIC ACID  
 PROFILE
After treatment with LGG, statistically significant changes between the treatment 
group and the placebo group were noticed only in the levels of kynurenate and 
3-indoleacetate (p<0.05 for both; IV). In the concentrations of organic acids that 
were different between CMA and eczema only -patients, a trend towards the eczema 
only -level was seen; the urinary levels of these organic acids decreased during LGG 
administration in CMA patients (Table 10).
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Table 10. (IV). Levels of urinary metabolic end products with significant dierences between CMA 
and eczema only –patients before (1.) or after treatment with LGG (2.).
The data are expressed in μg/mg creatinine after logarithmic conversion.
1. Statistical dierence between ezcema only and CMA groups. * = p<0.05; ** = p<0.01; ***  = p<0.001
2. Statistical dierence after LGG vs. Placebo treatment. # = p<0.05. 
Study phase 1. Before LGG treatment 2. After 4 weeks
Patient group Only eczema CMA CMA + LGG CMA + Placebo
Urinary metabolite mean ± SD mean ± SD mean ± SD mean ± SD
beta-hydroxybutyrate 0.51 ± 0.21 0.8 ± 0.22*** 0.70 ± 0.32 0.63 ± 0.28
adipate 0.64 ± 0.4 1.00 ± 0.26** 0.83 ± 0.22 0.89 ± 0.48 
isocitrate 1.8 ± 0.11 1.93 ± 0.11** 1.86 ± 0.1 1.98 ± 0.12 
homovanillate 0.82 ± 0.19 0.93 ± 0.08* 0.85 ± 0.06 0.92 ± 0.13 
kynurenate 0.67 ± 0.18 0.66 ± 0.15 0.71 ± 0.08 0.69 ± 0.11 #
suberate 0.39 ± 0.32 0.61 ± 0.18* 0.47 ± 0.22 0.63 ± 0.22 
tartarate 0.38 ± 0.21 0.64 ± 0.35* 0.26 ± 0.13 0.98 ± 0.2 
3-indoleacetate 1.06 ± 0.3 1.27 ± 0.27* 1.17 ± 0.29 1.47 ± 0.23 #
5-hydroxyindoleacetate 0.58 ± 0.31 0.78 ± 0.21* 0.76 ± 0.15 0.77 ± 0.41
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9. DISCUSSION
9.1. THIOL STATUS IN INBORN ERRORS OF METABOLISM
Inborn errors of metabolism such as organic acidaemias, mitochondrial diseases and 
disorders leading to hypoglycaemia all present with problems in energy production 
and nutrient metabolism. This series of studies has shown that these disorders are 
associated with changes in plasma thiol levels and redox states. These changes are 
suggestive of increased thiol oxidation and, possibly, decreased thiol antioxidant 
(GSH) supplies.
9.1.1. ROLE AND RELEVANCE OF PLASMA THIOLS 
In plasma, cysteine is the most abundant non-protein thiol. With levels exceeding a 
hundred-fold those of plasma glutathione, plasma cysteine is also more easily and 
reliably studied. Accordingly, the most significant changes we noticed in plasma 
thiols were in the plasma cysteine pool. Patients with mitochondrial diseases 
(II) and organic acidaemias (III) had evidence of increased plasma cysteine pool 
oxidation and lower plasma reduced cysteine levels. Reduced cysteine levels were 
also decreased in patients who became hypoglycaemic during fasting (I) and in 
patients with homocystinuria, who also had more cysteine bound to plasma proteins 
and, thus, a more oxidised plasma cysteine pool (unpublished data).
It is possible that plasma GSH was subjected to more subtle changes, and that 
similar differences would have been noticed in plasma GSH pool, had the number 
of patients and controls been greater. Indeed, several of the results suggest that. 
Patients with organic acidaemias (III) and mitochondrial diseases (II) mostly had 
plasma free GSH levels below the detection limit of the analysis, whereas most of 
the control patients had measurable concentrations. In organic acidaemias (III) and 
mitochondrial diseases (II) as well as in hypoglycaemic patients (I), a greater fraction 
of plasma total glutathione was bound to protein, which gives indirect evidence 
about oxidation of plasma GSH pool. In addition, in all of these patients and also 
in patients with homocystinuria, plasma total glutathione levels were lower than 
in controls; whether this is due to increased glutathione consumption or decreased 
glutathione synthesis – or both – cannot be stated, as GSH synthesis rates and 
fluxes were not studied. 
Plasma thiols represent the net sum of a complex interorgan homeostasis of 
different thiol pools. Some authors suggest that plasma thiol levels are correlated 
to intracellular thiol levels in other tissues, including the liver (Adams et al. 1983, 
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Jones 2002, Pastore et al. 2003), and represent a long-term view of thiol metabolism 
in the body (Taylor et al. 1992). This is not an unjustifiable view, and it certainly 
is a tempting one, as obtaining plasma samples for research is more feasible than 
obtaining liver or lung biopsies. 
Previous studies (Jones et al. 2002) suggest that the redox states of plasma thiol 
pools can be studied separately to gain understanding about the extent of oxidative 
events or the possible impairment of antioxidant defences.  Plasma cysteine/cystine 
pool seems to represent oxidative events of plasma thiols – the first line of defence, 
oxidised before other thiols – whereas that of glutathione would be indicative of 
plasma antioxidant capacity and the supply of antioxidants from tissues – the second 
line of defence. Thus, even if thiol levels in other tissues may not always be reflected 
in plasma thiol levels, the redox state of plasma thiols could represent thiol redox 
states in other tissues.
It seems reasonable to state that plasma thiol levels probably reflect thiol 
concentrations in other tissues only to some extent. Instead, rather than 
extrapolating plasma thiol levels to unstudied tissues, studying plasma thiols is 
relevant for gaining information about the redox environment cells are subjected to. 
If changes in plasma thiols are noticed, it may not be possible to state the origin of 
these changes with certainty, but changes in extracellular redox state will have major 
metabolic consequences. Changes in extracellular redox environment, manifested 
in an increased CYSH/CYSS oxidation such as we noticed in most studied patients 
(II, III), have been shown to be associated with inflammatory response, apoptosis 
signalling, and many different disease states; they have far-reaching effects to cell 
cycle gene expression and cell proliferation (Park et al. 2009, Jones et al. 2011). 
9.1.2. UNDERSTANDING THIOL STATUS BEYOND PLASMA THIOL LEVELS;   
 INTRACELLULAR THIOLS
In order to understand thiol status, studying intracellular thiol levels is mandatory. 
Obtaining tissue samples from paediatric patients, however, is problematic. In this 
series of studies (I, II, III), intracellular thiols are represented by erythrocyte thiols in 
all patient groups. In order to create intracellular conditions similar to the metabolic 
disturbances encountered in organic acidaemias and hypoglycaemia, we also studied 
intracellular thiols in human fibroblasts exposed to organic acids and in HEPG2 
and 293T cells deprived of glucose.
We noticed a significant increase in erythrocyte cysteine during hypoglycaemia 
(I). In order to study the effects of hypoglycaemia to thiol metabolism, erythrocytes 
are an optimal choice in the sense that they are dependent on glucose and glycolysis 
for their energy production. On the other hand, due to their glucose dependency, 
they may be less sensitive to low blood glucose concentrations. Erythrocytes are able 
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to transport glucose efficiently from rather low plasma concentrations, as the Km 
for the red cell glucose transporter, GLUT 1, is 1-2 mmol/l (Thorens et al. 1990). 
It is thus interesting that according to our results, blood glucose concentrations 
clearly exceeding that (2-3 mmol/l) had effects on erythrocyte thiols. 
Erythrocytes have high GSH synthesis rates, but they lack gGT activity (Srivastava 
1976) needed for GSH degradation for uptake and re-synthesis inside cells. Instead, 
erythrocytes transport the constituent amino acids cysteine, glycine and glutamate 
(in the form of glutamine) by specific sodium-dependent transporters (Raftos et 
al. 2010). The increase in erythrocyte cysteine cannot be explained by changes in 
cysteine availability, as plasma free cysteine levels during hypoglycaemia were low. 
Even if cysteine is glucogenic, cysteine is not targeted for energy metabolism in 
erythrocytes, as gluconeogenesis from amino acids mainly takes place in the liver 
and, possibly, in the kidneys and intestine during extended fasting (Mutel et al. 2011). 
Instead, the  increase in erythrocyte free cysteine during low blood glucose may be 
seen as an antioxidant response aiming at increasing intracellular GSH synthesis in 
erythrocytes. As erythrocyte total glutathione levels remained unaffected by blood 
glucose, increased GSH synthesis did not take place during hypoglycaemia, possibly 
following impaired synthetic capacity and lack of ATP energy. 
In cultured HEPG2 cells, 28-hour glucose deprivation lead to loss of free and total 
glutathione, whereas CYSH and total cysteine values did not change markedly during 
glucose deprivation (unpublished data). Thus, GSH levels in HEPG2 cells, which 
are an in vitro model of human hepatocytes, decreased either following deficient 
capacity to synthesise GSH, or following increased GSH export due to an increase 
in oxidative stress in other tissues. 
On the contrary, in cultured 293T cells originating from human embryonic kidney 
cells, 24 h glucose deprivation lead to an increase in both CYSH and GSH levels; also 
total cysteine ad glutathione levels increased (unpublished data). However, when 
glucose deprivation was prolonged to 48 h, both CYSH and GSH and corresponding 
total thiol levels decreased clearly. Renal tubular cells have high gGT activity and are 
thus able to take GSH from the extracellular space for breakdown and intracellular 
resynthesis of GSH. It seems that glucose deprivation induced GSH synthesis from 
its constituents, but that after prolonged glucose deprivation, the cells’ synthetic 
capacities became compromised.
Tumour cell lines (such as HEPG2) have an altered thiol metabolism as compared 
to healthy cells in a living organism; in addition, separate cell culture models can 
hardly mimic the complex interorgan metabolism of thiols. Still, our results with 
glucose-deprived 293T and HEPG2 cells fit quite well into current knowledge on 
the roles of different cells and tissues in thiol metabolism. During oxidative and 
metabolic stress, as occurs in hypoglycaemia, liver cells supply GSH for the use of 
other cells and tissues with high gGT activity, such as the kidney.
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9.1.3. THE ROLE OF SOME DIETARY AND METABOLIC FACTORS IN THE   
 ALTERED THIOL STATUS IN INBORN ERRORS OF METABOLISM
9.1.3.1. Protein-restricted diet may lead to changes in thiol status in organic 
 acidaemias 
We hypothesised that dietary protein restriction, even if the diet is balanced to 
meet specific amino acid requirements, may affect thiol status in certain metabolic 
disorders such as organic acidaemias. According to previous studies, dietary sulphur 
amino acid intake influences plasma free cysteine levels, with low intake leading 
to low plasma free cysteine concentrations and thus a more oxidised CYSH/CYSS 
redox state (Jones et al. 2011). According to the same study, these changes were 
not directly reflected in plasma GSH levels even if dietary sulphur amino acid 
intake (cysteine availability) mainly controls the rate of GSH synthesis. Blood GSH 
synthesis rates (but not necessary GSH levels) diminish when sulphur amino acid 
intake is inadequate (Lyons et al. 2000, Lyons et al. 2001), and even suboptimal – 
not insufficient - protein intake may decrease GSH synthesis (Stipanuk et al. 1992, 
Jackson et al. 2004). 
Our results with patients with organic acidaemias (III) – low plasma free cysteine, 
more oxidised plasma cysteine pool, and decreased plasma total glutathione – 
are in line with these findings. Thus, the protein-restricted diet, even if matching 
nutritional recommendations, may be one explanation to the changes in thiol status 
of patients with organic acidaemias.
9.1.3.2 Influence of other dietary factors to thiol status: diurnal variation in  
 plasma thiols
Plasma thiols show some diurnal and meal-associated variation. In one study with 
healthy adults (Blanco et al. 2007), plasma cysteine (CYSH) levels increased after 
meals, and plasma CYSH/CYSS redox state became more reduced towards the 
evening. Interestingly, this was followed by similar changes in plasma GSH and 
GSH/GSSG with a 6-hour delay. We measured plasma thiols simultaneously, and 
thus the possible delayed effects of the changes we noticed in plasma CYSH/CYSS 
status would not have been detected. 
As for the diurnal variation in plasma thiols, all the samples in our study (I, 
II, III) were taken in the morning after an overnight fast; it is not likely that the 
patients would have had different diurnal patterns from the controls. However, 
patients with metabolic diseases and especially those with organic acidaemias and 
hypoglycaemic episodes have very special diets and eating patterns, sometimes also 
including frequent meals due to intolerance to fast. One could speculate about this 
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having an influence on the meal-associated variation in plasma thiols even if sulphur 
amino acid intake is not affected. However, our results – low free cysteine levels 
and redox states in patients with organic acidaemias and mitochondrial diseases 
– do not directly support this hypothesis.
9.1.3.3. Poor nutritional status and need for protein may underlie changes in  
 plasma thiols
There was a positive correlation between blood glucose and free cysteine (I); low 
blood glucose was associated to low free cysteine levels. Cysteine is a glucogenic 
amino acid; it is possible that in the patients with lowest blood glucose, blood 
cysteine decreased following cysteine uptake in the liver for gluconeogenesis. 
Alternatively, it could be hypothesised that those with an ability to liberate amino 
acids, including cysteine, to be then used by the liver for glucose production did 
not become hypoglycaemic. Thus, nutritional status and protein intake might not 
have been adequate in the patients with low cysteine. This explanation is, however, 
unlikely, as total cysteine levels did not differ between patients and controls.
Patients with mitochondrial diseases (II) and organic acidaemias (III) also had 
lower plasma free cysteine levels. In both diseases, lack of substrates for (protein) 
energy metabolism may occur (in mitochondrial diseases following failure of 
efficient energy production and in organic acidaemias, following low-protein diet). 
Patients with mitochondrial diseases (II) and organic acidaemias also had lower total 
glutathione levels (III). This may reflect poor nutrition and need for more protein. 
Either GSH synthesis in the liver was impaired due to lack of protein, or a decrease 
in plasma GSH may be due to the amino acid transporter role of GSH (Meister and 
tate 1976). Tissues with high gGT activity may be responsible for an increased GSH 
degradation and uptake of constituent amino acids for protein synthesis.
9.1.3.4. Metabolic blockage in homocystinuria may explain decreased cysteine  
 and glutathione levels
In homocystinuria due to CBS deficiency, the metabolic pathway generating cysteine 
from methionine is blocked (Mudd et al. 2001); homocysteine is an intermediate 
in the transsulphuration pathway (Figure 2), which regenerates cysteine from 
methionine. Thus, patients with homocystinuria due to CBS deficiency or defect 
have absent or decreased ability to make cysteine, which is normally not an 
essential amino acid. This could lead to lack of cysteine, and accordingly, we 
noticed significantly decreased plasma cysteine levels. Logically, this may also 
lead to decreased GSH synthesis, as cysteine is the rate-limiting component of GSH 
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synthesis; indeed, decreased total plasma glutathione was observed in patients 
with homocystinuria.
Thus, patients with homocystinuria not only have altered plasma thiols following 
hyperhomocysteinaemia, where abnormally high levels of homocysteine disrupt 
other plasma thiol pools by thiol-disulphide reactions (Di Giuseppe et al. 2004); 
the metabolic blockage in CBS deficiency may also lead to secondary changes in 
thiol levels following defects in non-protein thiol synthesis.
9.1.4. PHYSIOLOGIC VARIATION IN PLASMA THIOLS 
Due to the small number of patients and controls, it was not possible to control 
for the possible confounding factors that arise from physiologic variation in thiol 
levels related to age, sex, diet, physical activity, diurnal variation etc., overviewed 
in 5.5.1. and in Table 4. Possible effects of the diet on thiols were part of the study 
hypothesis, and it was not meaningful to control for those. All samples were taken 
in the morning after an overnight fast, so the possible confounding effects of fasting 
and daytime were controlled to a sufficient degree. 
Our patients and controls were not matched for age; age is known to influence 
plasma thiols (Jones et al. 2002) at least in older age groups (middle age and 
after). Age-related variation in thiol levels in healthy children has not been studied 
thoroughly. In one study (Di Giuseppe et al. 2004), plasma reduced and oxidised 
thiols (plasma cysteine, glutathione, homocysteine and cysteinylglycine and 
corresponding disulphides) remained fairly constant after the newborn period 
throughout the childhood and puberty. Age-related physiologic variation (a decrease 
in plasma thiol redox status) was observed only when comparing newborns to 
other subjects or after 50 years of age. Our patients and controls were all between 
1 and 16 years old; thus, even if the evidence is not exhaustive, it seems that our 
results on plasma thiols should not be biased by the different age distribution in 
the patient and control groups.
For future studies, it could be feasible to choose matched controls (at least 
matched for age and sex), as this would reduce the number of controls needed 
for enhancing statistical power. Variables possibly affecting thiol levels (age, sex, 
physical activity etc.) could be better controlled for. In addition, a pre-study power 
analysis would enhance the statistical validity of results; even if the number of 
patients was limited for obvious reasons, a power analysis would probably have 
led to increasing the number of controls in this series of studies.
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9.2. ALTERED THIOL STATUS AS AN INDICATOR OF OXIDATIVE  
 STRESS IN INBORN ERRORS OF METABOLISM
GSH has multiple different roles, but its main purpose is related to its 
antioxidant function. However, due to complex interorgan and intracellular 
compartmentalisation, glutathione levels are not straightforward markers of 
oxidative stress or antioxidant reserves.
In this series of studies (I, II, III), to address these questions, glutathione 
antioxidant function was studied from several points of view. First, both GSH and 
its precursor cysteine levels were studied intracellularly and extracellularly; second, 
GSH antioxidant function was investigated by measuring several GSH-dependent 
antioxidant enzyme activities. Finally, to gain understanding about the ultimate 
consequences of a possible increase in oxidative stress, oxidative damage to tissue 
proteins and lipid was studied.
The results of this series of studies support the idea of oxidative stress, here 
reflected in a change in plasma thiol status, playing a role in the disease process of 
organic acidaemias, hypoglycaemic episodes and mitochondrial diseases. Whether 
this is due to inadequate thiol antioxidant production, impaired function or increased 
consumption, cannot be fully understood with our results, as we did not find direct 
evidence of differences in antioxidant function (expressed by thiol antioxidant 
enzyme activities) or oxidative damage.
9.2.1. CHANGES IN PLASMA THIOL STATUS WITHOUT ANTIOXIDANT RESPONSE  
 OR OXIDATIVE DAMAGE IN ERYTHROCYTES 
We found evidence of changes in plasma thiol status, suggestive of an increase in 
oxidative stress, in several metabolic diseases. Still, there were no significant changes 
in erythrocyte antioxidant enzyme activities, nor was there evidence of an increase in 
oxidative damage to erythrocytes. The absence of a significant change in erythrocyte 
GSH-dependent antioxidant enzyme levels despite changes in plasma thiol status 
may suggest that the patients with mitochondrial diseases, hypoglycaemia and 
mitochondrial diseases were unable to produce an appropriate antioxidant response 
following increased thiol oxidation and compromised function of antioxidant systems. 
The samples were taken under routine control visits, when the patients were 
not acutely ill or metabolically decompensated. Thus, oxidative stress, reflected in a 
change in plasma thiol status, seems to be present at all phases in these metabolic 
disturbances. This supports the role of oxidative stress in the pathophysiology of 
metabolic disorders; it not only occurs at a late stage when overwhelming metabolic 
stress, impairing all control mechanisms and leading to tissue damage, is present, 
but also throughout the disease. 
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As oxidative stress is a dynamic state between two players – antioxidant defences 
and free radical generation – it is not straightforward to interpret the results of 
antioxidant enzyme activities during oxidative stress. An increase in antioxidant 
enzyme activity may be seen as a stress response to an increase in free radical 
generation, or a measure preventing oxidative damage in healthy tissues. A decrease 
in antioxidant enzyme activity may reflect deficient antioxidant capacities, or a 
metabolic state with low ROS production and abundant antioxidant supplies. 
Indeed, in previous studies on antioxidant enzymes in metabolic disorders, the 
results about the association these enzymes to otherwise detected oxidative stress 
are contradictory. During hypoglycaemia, GPx activity has been reported to decrease 
(Koska et al. 2000), to remain unchanged (Patockova et al. 2003), or to increase 
(Singh et al. 2004). Similarly, during compromised mitochondrial function, GPx 
activity has been shown to increase (Auchère et al. 2008), decrease (Wani et al. 
2008) or be equal to controls (Tozzi et  al 2002). 
Our results on enzyme activities and oxidative damage need, however, to be 
interpreted with caution. The number of patients and controls was small and the 
variations wide, possibly leading to absence of a statistically significant difference. 
In addition, our results (no increase in MDA an protein carbonyls in erythrocytes of 
patients with metabolic diseases) do not exclude the possibility of oxidative damage 
occurring in other tissues than erythocytes in response to the oxidation of plasma 
thiols. However, previous studies have shown that a change in extracellular redox 
status is not necessarily reflected to intracellular redox state (Imhoff et al. 2007), 
thus making intracellular oxidative damage unlikely. We used a TBA-RS –based 
assay to measure MDA levels as a marker of lipid peroxidation; the assay, however, 
has low ability to detect some products of oxidative damage to lipids, including 
oxidation products of arachidonic acid (De Zwart et al 1999). 
In order to better understand the intracellular effects of altered plasma 
thiol status, complementary methods would be needed. These could include 
expression of oxidative stress –induced transcription factors and more 
exhaustive methods to study oxidative damage, including isoprostane analysis 
to detect the products of arachidonic acid oxidation (DeZwart et al 1999), and 
a method such as the 8OHdG assay to screen for oxidatively damaged nucleic 
acids (Halliwell 2007).
9.2.2. ROLE OF ERYTHROCYTES IN STUDYING THIOL ANTIOXIDANT SYSTEMS 
Erythrocytes, although rich in antioxidant systems, have no nucleus and are thus 
very special cells. Due to the absence of protein synthesis in erythrocytes, they 
cannot be studied to gain understanding about possible changes in transcription 
activity of antioxidant enzymes, or enzymes affecting thiol metabolism. However, 
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erythrocytes are continuously exposed to high oxygen concentrations due to their 
role as oxygen carriers. Moreover, they are prone to ROS formation by the Fenton 
reaction due to the presence of high levels of transition metals (iron in the haem) 
(Halliwell 1991; Kurata et al. 1993). 
Erythrocytes have deficient capacity to respond to oxidative stress due to the 
inability to respond by a change in transcription activity or synthesis of antioxidant 
enzymes. Thus, in many other respects, erythrocytes are relevant cells for studying 
oxidative damage, and also some forms of antioxidant responses, including thiol 
levels ant thiol antioxidant enzyme activity. Erythrocytes are fairly easily available 
for analysis even in a paediatric study setting, and they have thus often been used 
previously, facilitating comparison of results.
9.3. DETERMINATION OF THIOLS IN BIOLOGIC SAMPLES IS   
 TECHNICALLY DEMANDING; LIMITATIONS OF THE STUDY
9.3.1. LOSS OF THIOL GROUPS AFTER SAMPLING
Measuring intra- and extracellular thiol levels and their redox state poses several 
technical problems due to the short half-time of the species and their predisposition 
to oxidation-reduction reactions (Jones et al. 1998; Newton and Fahey 1995). 
Intracellular thiol (mainly GSH) levels and especially their redox state may be 
strongly influenced by thiol auto-oxidation during sample procession, e.g. during 
haemolysis of erythrocytes for analysis. In addition, intracellular thiol-metabolising 
enzymes (GPx, GR etc.) may affect thiol redox states after sampling (Hwang et 
al. 1995). As intracellular GSH/GSSG pool is maintained at a very reduced state, 
even a small increase in GSSG due to sample auto-oxidation or post-sampling 
enzymatic activity would have a significant influence to the measured glutathione 
redox state. Intracellular GSH is also compartmentalised to cytosolic, endoplasmic 
and mitochondrial pools, and their participation to the measured intracellular thiol 
levels may be unpredictable (Hwang et al. 1995).
We only measured intracellular total thiols in patient samples, which minimises 
the previously described methodological problems. However, total thiols only 
represent the net sum of thiol oxidation-reduction reactions and also thiol (GSSG) 
efflux, and the interpretation of these is not straightforward. For instance, the 
increase in intracellular total cysteine in hypoglycaemic patients may result from 
increased cysteine uptake or decreased cysteine use for GSH synthesis. Any decrease 
in intracellular total GSH may be due to an increase in GSSG efflux, or decrease in 
GSH synthesis. On the other hand, if GSH use in antioxidant reactions increased, 
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this would remain unnoticed; if no significant GSSG export occurs, total GSH levels 
would remain unchanged, as was possibly the case in our studies.
Measurement of plasma (or extracellular) thiols is prone to similar artefacts 
following suboptimal sample collection and sample processing techniques. 
Especially measurement of plasma GSH levels is demanding, as the values are 
in the micromolar range. GSH in plasma is also very short-lived with a half-time 
of a few minutes at room temperature (Wendel and Cikryt 1980), and plasma 
gGT activity may contribute to plasma GSH degradation under some special 
circumstances (Jones et al. 1998). Most importantly, erythrocyte GSH levels are 
500 times above plasma levels; thus, even 0.1% haemolysis (Jones et al. 1998) 
during blood sampling or before plasma separation may increase plasma GSH 
levels substantially. 
When taking blood samples from children, the risk for unintentional haemolysis 
and artefactual thiol oxidation is even greater than in adults due to small veins, small 
needles used for venipuncture and to the need for using a tourniquet. Interestingly, in 
a previous study (Di Giuseppe et al. 2004), newborn subjects had increased plasma 
thiol and especially GSH oxidation when compared to older children or adults; the 
authors do not discuss the possible influence of technically difficult blood sampling 
leading to artefactual loss of blood GSH in the newborn period. These problems 
can hardly be avoided in an out-patient setting where arterial blood sampling is not 
possible. It would, however, be possible to include a marker for haemolysis (such 
as plasma haemoglobin) in plasma thiol analyses. 
9.3.2. LACK OF REFERENCE VALUES – NEED FOR A CONTROL GROUP AND 
ADEQUATE NUMBER OF PATIENTS AND CONTROLS
Plasma GSH levels from different laboratories are not necessarily comparable. 
For instance, GSH levels in human plasma vary over 10-fold in the literature, 
depending on the analytical procedure used (Jones et al. 1998). It is not clear which 
analytical procedure is the most reliable (Meister and Anderson 1983), although 
monobromobimane-based thiol group alkylation followed by HPLC analysis, as was 
used in this series of studies, has been shown to be useful and reliable (Meister and 
Anderson 1983, Newton and Fahey 1995). Even using similar monobromobimane 
-based HPLC methods, reported plasma GSH values vary from under 1 mmol/l to 
3-6 mmol/l (Jones et al. 1998). 
Thus, it may not be possible to compare our absolute results with previous ones; 
that is also why the use of a control group, sampled and analysed identically with the 
patients, was mandatory. It would certainly have been ideal to include more children 
to the control group. Having a small number of controls implies a risk for type II 
error; especially in a study with a limited number of patients, a greater number 
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of controls would improve statistical validity of results. Obtaining relevant control 
samples is a difficult issue in clinical studies, and it is even more problematic, for 
obvious ethical reasons, when paediatric patients and controls are concerned. In this 
study, the small number of patients and controls is, to some extent, compensated 
by the fact that the controls were well chosen. They lived in the same area, where 
of similar age, and were thoroughly studied and found to be healthy. 
The number of patients was small, which is inevitable as the studied diseases 
are very rare; this leads to a risk for both type I and II errors. In addition, for the 
same obvious reason, it was not possible to make a pre-study power calculation to 
estimate the number of patients and controls needed to reach satisfying statistical 
power. As we studied thiol metabolism from several points of view, we did not 
have a single hypothesis to test; this makes the study prone to type I errors due 
to multiple comparisons between patients and controls. However, as results with 
different metabolic diseases affecting energy and nutrient metabolism were very 
much alike – increased plasma thiol oxidation and decreased plasma glutathione 
levels – the results of multiple comparisons gain additional validity. Moreover, 
the objective of the study was to find new ideas for pathogenetic factors, but not 
directly to find new means of treatment. Thus, the risk of performing a type I error 
is ethically less problematic than type II error, which would lead to omitting true, 
possibly important, differences between patients and controls. 
More patients (and controls) could have been recruited only by including 
multiple specialised centres from different countries, which could hardly have been 
justified when dealing with this kind of preliminary study hypothesis. Now that 
some metabolic diseases clearly are associated to changes in thiol metabolism, 
it would be of interest to study more patients and also GSH levels in tissues or 
cultured cells from patients.
9.4. ROLE OF THIOLS IN THE PATHOGENESIS OF    
 COMPLICATIONS IN INBORN ERRORS OF METABOLISM 
9.4.1. THIOLS, NEURODEGENERATIVE DISEASES AND NEUROLOGICAL   
 SYMPTOMS IN INBORN ERRORS OF METABOLISM 
Many inborn errors of metabolism present with neurological symptoms, and also 
complications of hypoglycaemia are due to neuronal damage. Some patients with 
inborn errors of metabolism, e.g. those with organic acidaemias, may also have 
structural brain abnormalities (Wajner et al. 2004), suggesting a disease mechanism 
profoundly influencing neuronal differentiation, function and survival.
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Glutathione has a critical role in the central nervous system; besides being an 
antioxidant, it has been shown to have other neuroprotective and neuromodulative 
roles (Janáky et al. 1999, Oja et al. 2000, Ballatori et al. 2009 b). The clinical (or 
therapeutic) significance of these findings linking GSH to neuronal survival and 
central nervous system function is not clear, but the association is interesting. Inborn 
errors of GSH metabolism all present with central nervous system involvement, and 
low GSH have been reported in various neurodegenerative disorders (Ballatori et al. 
2009 b), Sabens et al. 2011.) – including, as has been reviewed in this thesis, several 
inborn errors of metabolism. It seems that alterations in sulphydryl homeostasis 
leading to changes in redox signaling and regulation influence the pathogenesis of 
neurodegenerative diseases (Sabens et al. 2011).
The possible neuromodulative roles of GSH form an interesting, yet hypothetical, 
link between the observed changes in thiol metabolism and the poorly understood 
neuropathology in many inherited metabolic disturbances, including organic 
acidaemias, mitochondrial diseases and hypoglycaemic neuronal damage. To further 
evaluate this hypothesis, thiols in cells of neuronal origin should be studied. 
9.4.2. ALTERED THIOLS AND ATHEROSCLEROSIS IN HOMOCYSTINURIA
Patients with homocystinuria often present with cardiovascular and thromboembolic 
complications (Clarke 1991), and elevated levels of homocysteine are associated to 
an increased risk of cardiovascular complications also in the general population 
(Homocysteine studies collaboration 2002).
The exact disease-causing mechanisms of elevated levels of homocysteine are 
unknown, but oxidative stress due to the pro-oxidant properties of homocysteine 
in blood has been suggested as an explanation (Welch and Loscalzo 1998). 
Homocysteine, when present at high levels, participates in thiol redox status and 
is able to form mixed disulphides with other plasma non-protein thiols and protein 
thiol groups (DiGiuseppe et al. 2004). It thereby significantly influences extracellular 
redox status and redox regulation. Accordingly, we found that patients with 
homocystinuria had clear changes in their plasma thiols with lower total glutathione 
and total cysteine levels. Even if we could not show a significant change in their 
plasma thiol redox state, there was indirect evidence of increased plasma cysteine 
oxidation (unpublished data).  
Thus, homocystinuria is associated to altered plasma thiol levels and an altered 
plasma thiol redox state due to the ability of homocysteine to participate to thiol-
disulphide reactions and disrupt extracellular thiol status. This forms an interesting 
link between the poorly understood pro-oxidant nature of homocysteine, oxidative 
stress and atherosclerosis in homocystinuria.
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9.5. ALTERED THIOLS IN METABOLIC DISEASES; POSSIBILITIES  
 FOR THIOL TREATMENT? 
This thesis, focusing on thiols and their metabolism, did not concentrate on 
antioxidants, nor did the studies include antioxidant treatment.  As we noticed 
changes in thiol status suggesting an increase in oxidative stress and a relative GSH 
deficiency, it is, still, tempting to speculate on the therapeutic implications these 
findings could have. Thiol status can be affected by adequate nutritional sulphur 
amino acid intake and, failing that, by thiol antioxidant supplementation.
As reviewed in 5.5.4, GSH as such cannot be used as a therapeutic agent. Despite 
intensive research, knowledge on the optimal product to improve GSH levels is still 
incomplete. Among agents that are targeted to increase cellular GSH levels, lipoic 
acid (1,2-dithiolane-3-pentanoic acid, or thioctic acid) is a promising one. It has 
been shown to increase intracellular thiol levels, and as a thiol antioxidant, it is 
able to truly participate to the complex mechanisms involved in the regulation of 
thiol redox status and redox signalling. In addition, compared to GSH or cysteine 
prodrugs, it better studied in vivo and even used clinically (Shay et al. 2009).
In fact, in most clinical situations, despite a well-justified scientific basis and 
clinical evidence of oxidative stress, antioxidant trials have failed; even with intensive 
research, antioxidant supplementation still remains a question of debate, and 
according to a meta-analysis, they may even be harmful (Bjelakovic et al. 2007). Even 
in disorders like mitochondrial diseases where excessive free radical production very 
clearly plays a role, evidence does not support the use of antioxidants (Chinnery 
et al. 2006). 
It is probable that part of the problem is due to fact that knowledge on the 
mechanisms of action of specific antioxidants and, particularly, the interplay 
between different antioxidant systems is incomplete (Bjelakovic et al. 2007). Many 
antioxidant systems act in collaboration with each other, and the effects of depletion 
– or supplementation – of a single antioxidant are not predictable. In addition, 
most trials have used combinations of antioxidants without a clearly defined target 
antioxidant system. As many antioxidants may also have pro-oxidant effects, the 
optimal dosage of a particular antioxidant should have been determined before 
clinical trials. Due to this dual antioxidant/pro-oxidant character, it is also possible 
that the effects of an antioxidant in diseased cells or tissues will differ from those 
in healthy cells often used in study settings (Coleman et al. 2007). 
Administering antioxidants such as a-linoleic acid (vitamin E) or ascorbic acid 
(vitamin C), as has been done in many clinical trials (Bjelakovic et al. 2008), may 
be too many steps upstream in the cascade initiating the disease process. From 
this point of view, understanding the role of thiols is relevant, notably following 
the ubiquitous roles thiols play in cellular survival and regulation. When a change 
in thiol status is noticed, it is possible to target interventions to thiol metabolism 
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– not just to administer any antioxidant in the hope of reducing oxidative stress 
arising from unknown sources. 
Obviously, more research and understanding on the role of thiols in metabolic 
disturbances is needed before considering any therapeutic approaches. In addition, 
in vivo studies on thiol supplementation are lacking (with, perhaps, the exception 
of lipoic acid), even if numerous promising products have been developed. 
9.6. CMA AND ALTERED URINARY METABOLIC END PRODUCTS
The urinary organic acid profile was altered in children with CMA as a sign of 
metabolic changes in the intestine due to either inappropriate nutrition and/ or 
differences in intestinal microbiota and its metabolic activity. The differences we 
noticed in urinary organic acid excretion in a clinically relevant diagnostic setting– 
infants with atopic eczema, but with or without CMA – may offer interesting new 
potential for CMA diagnosis.
9.6.1. A MODEL FOR FOOD INTOLERANCE? THE ROLE OF URINARY   
 β-HYDROXYBUTYRATE AS A MARKER OF INAPPROPRIATE NUTRITION
Situations with inadequate nutrition, due to restricted or inappropriate diet or 
impaired nutrient absorption, are numerous. Despite their heterogeneous origins, 
they might share common metabolic consequences. Cow’s milk allergy is the 
prototype of food allergy and may also be viewed as a model mechanism of any 
food intolerance and inappropriate nutrition in early infancy, when milk is the 
main nutrition.
Interestingly, we noticed a significant increase in urinary excretion of 
b-hydroxybutyrate in patients with CMA. b-hydroxybutyrate, along with acetoacetate, 
is a ketone body that is excreted to urine in larger amounts during ketosis, i.e. when 
body fats are liberated for energy metabolism. This occurs normally during fasting, 
prolonged physical exercise, or during high-fat (or low-carbohydrate) diet when the 
lipolysis of fats to acetoacetate exceeds the capacity of carbohydrate metabolism to 
produce oxaloacetate to be joined with acetoacetate in the citric acid cycle (Cahill 
2006).
The infants in this study were not fasted. It is also reasonable to assume that the 
physical activity was equal in patients and controls, the mean age being 6 months. 
Thus, the rise in urinary ketones in patients later diagnosed with CMA may not be 
a sign of altered bacterial metabolism but, instead, reflect a metabolic change in 
the patients in response to prolonged inappropriate nutrition. The ketosis in these 
patients could be a chronic state similar to fasting, but due to inadequate use of 
97
nutrition following intestinal inflammation resulting from intolerance to milk, the 
main nutrient in this age group. 
It could also be argued that children less than one year of age with intestinal 
symptoms suggestive of food allergy would have had less varied diets with respect 
to the initiation of solid foods than their controls. Thus, food allergic children would 
be receiving more milk and, possibly, more fat – and their elevated urinary ketone 
bodies could only be due to a high-fat-low-carbohydrate diet. The study protocol 
assured that all infants were exposed to CM before the sample was taken, but their 
diet was not specified in other respects. Thus, this possible explanation, although 
unlikely, cannot be excluded.
9.6.2. FROM BACTERIAL METABOLITES TO METABOLIC PROFILING
CMA is a common condition but, unfortunately, its diagnosis is often challenging 
due to unspecific symptoms and laborious diagnostic protocols as explained earlier 
(5.2.).  Recently, probiotics have been extensively studied (and marketed) in allergic 
diseases, but their role is still far from clear. In addition to their contribution to 
the composition of intestinal microbiota, probiotics also enhance intestinal barrier 
function, and some of their effects may be due to changes in the metabolic activity 
of intestinal microbiota following probiotic colonisation (Madsen et al. 2001, 
Rosenfeldt et al. 2004). Understanding the metabolic abnormalities and, eventually, 
the metabolic mechanisms of probiotic action in CMA could provide new approaches 
to the diagnosis and treatment of CMA.
9.6.2.1. From analysis of bacterial species to microbial metabolite recognition
Studying bacterial metabolites such as bacterial SCFA offers remarkable benefits 
in comparison to studying the bacteria themselves; namely, only 40% on bacterial 
species in human intestine are culturable outside the gastrointestinal tract (Sandin et 
al. 2009). Gene technology, e.g. 16S rRNA –based identification of different bacterial 
species now provides more sensitive means to study bacterial species themselves 
(Zoetendal et al. 2006); however, to understand bacterial function and host-microbe 
interactions, studying bacterial metabolites still remains indispensable. 
Metabolites from the intestinal microbiota are not only relevant in gaining 
information about the microbial species. End products of bacterial metabolism 
also influence the host metabolism. Intestinal microbiota synthesise vitamin K for 
the host and participate to calcium and iron absorption. In addition, bacterial SCFA 
participate to host metabolism. Butyrate produced by intestinal bacteria has trophic 
properties to intestinal epithelium by serving as an energy source to colonocytes; 
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acetate and propionic acid modulate the host’s glucose metabolism; all three acids 
stimulate proliferation and differentiation in intestinal epithelial cells (Guarner and 
Malagelada 2003, Guarner 2006).
9.6.2.2. Urinary versus faecal metabolite excretion; biologic variation related to  
 age, diet and medication
According to previous studies, the development of allergy in children is associated 
with higher amounts of faecal SCFA, and a different SCFA profile with lower levels 
of i-butyrate, (i-)valerate, and propionate and more i-caproate in children later 
developing or already having  allergy (Böttcher et al. 2000, Kalliomäki et al. 2001 
a), Norin et al. 2004, Sandin et al. 2009). In our study, the urinary excretion of 
these acids was not changed in children with CMA; instead, we found higher urinary 
levels of b-hydroxybutyrate, adipate, isocitrate, homovanillate, suberate, tartarate, 
3-indoleacetate and 5-hydroxyindoleacetate.  
It is interesting that the urinary metabolic profile in our study does not seem to 
correlate with the previous faecal SCFA patterns in allergic infants. We compared 
food allergic children to atopic (eczematous) children without food allergies, as 
our aim was to find markers for inappropriate nutrition due to food intolerance; in 
previous studies, the focus has been on comparing allergic children to non-allergic 
ones. The fact that similar metabolic differences that we noticed have not been 
found in other studies with allergic children may strengthen the hypothesis that 
the differences we noticed were inherent to the intestinal food allergy itself, not 
just a by-product of atopic predisposition as different faecal SCFA patterns may be.
From studies on faecal SCFA patterns, it is known that factors such as age, diet 
and antibiotic or probiotic intake influence the results. According to Böttcher et 
al. (2000), age and the length of breast-feeding influence faecal SCFAs in under 
9-month-old infants, but not in elder children. It is reasonable to assume that 
variation due to these factors could occur in urinary metabolite levels as well. In 
our study, antibiotic and probiotic intake were controlled. Except for the obligatory 
exposure to CM in some form, the diet of the patients and controls was not controlled 
in other ways, and some changes could arise from differences in the diet. However, 
as both the patients and controls were on average 6 months, their diets were fairly 
similar, mainly consisting of milk. The patients and controls in the study cohort 
as a whole were breast-fed for an equal time, and cow’s milk was introduced at a 
similar age in all groups. Although unlikely, it cannot be excluded that the patients 
and controls of our study population, which was randomly selected form the larger 
study cohort, would have been different in these respects.
Naturally, the results of faecal and urinary metabolite profiles are not directly 
comparable: all of the metabolites measurable in faeces may not be excreted in 
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urine, or they may be metabolised by the host before urinary excretion. On the 
other hand, urinary metabolites may reflect a long-term metabolic state (Maher 
et al. 2007), whereas faecal SCFA profile may be more labile and subject changes 
following differences in the diet, received antibiotics, age etc (Böttcher et al. 2000).
We did not control for possible faecal contamination, which would influence urinary 
levels of bacterial SCFA. Faecal contamination may always take place when taking 
urine samples from infants using an adhesive urine bag, although the techniques we 
used (bag replacement every 2h, immediate cooling of the sample) minimise the risk. 
The technique of urinary sampling could not have been modified, as sterile techniques 
(catheter or suprapubic puncture) would not have been ethically justifiable in this 
patient group. However, it would be possible to involve urinary bacterial cultures in the 
study protocol to control for the possibility of faecal contamination of urine samples; 
still, it would leave the majority of bacterial species undetected, as approximately 40% 
of intestinal microbes are culturable (Sandin et al. 2009). 
9.6.2.3. From urinary metabolites to metabolic profile and metabolomics
Urinary excretion of substances may provide an insight into a long-term metabolic 
balance. Urinary levels, however, represent the net sum of many different metabolic 
processes over a longer time course. Rather than making statements about levels of 
single substances in urine, it seems necessary to look after urinary patterns or urinary 
profiles, which is increasingly being done in metabolomics (Theodoridis et al. 2012). 
The idea is to scan by a sensitive method – either liquid or gas chromatography/
mass spectrometry -based methods or nuclear magnetic resonance spectroscopy – 
for all possible metabolites in a biologic sample and then look after specific profiles 
or patterns by multivariate statistical analysis.
Analysing metabolic profiles rather than single metabolites makes it possible 
to take a holistic approach to metabolism and see it as a sum of multiple parallel 
chemical reactions, which it truly is. This field in metabolic studies is still new, 
and studies from different laboratories not yet directly comparable (Theodoridis 
et al. 2012).  Our small study population did not make it possible to make relevant 
statistical analysis of the true urinary metabolic profiles, not to mention the 
metabolome, of our patients, but this could be feasible in further studies. 
9.6.3. POSSIBILITIES FOR DIAGNOSIS 
Food allergies cause chronic inflammation of the gut (Mansueto et al. 2006), 
which affects intestinal absorptive function and increases intestinal permeability 
by disrupting the epithelial barrier (Macdonald and Monteleone 2005). Atopy and 
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allergies are also associated with changes in intestinal microbiota (Bjorksten et al. 
1999, Kirjavainen et al. 2001) and its metabolic function (Ouwehand 2007). The 
causality between food allergies, changes in intestinal microbiota and increased 
intestinal permeability are not clear; it seems that altered microbiota induces 
intestinal inflammation leading to altered intestinal permeability, but individual 
immunologic factors then determine whether changes in permeability result in 
the development of tolerance or intolerance. Ideally, the absorption – or leakage 
–of normally unabsorbed compounds from the gut could be used as a marker of 
altered intestinal permeability and bacterial metabolism, and even as a diagnostic 
tool for food allergies. 
9.6.3.1. Urinary lactulose/mannitol ratio as a marker of intestinal permeability  
 and food allergy
Children with food allergies have different intestinal permeability to specific 
compounds as compared to healthy controls (Jackson et al. 1981); the permeability 
to small molecules (e.g. mannitol) seems to be identical, but the permeability to 
large, normally unabsorbed, molecules (e.g lactulose) increased  (Andre et al. 1987, 
Laudat et al. 1994). The ratio of permeability to lactulose and mannitol (measured 
as the recovery of lactulose and mannitol in urine after oral lactulose and mannitol 
load) has been suggested to be a marker of allergy-related change in intestinal 
permeability and, eventually, as a diagnostic method (Andre et al. 1987, Dupont 
et al. 1989, Laudat et al. 1994).
Many studies, however, show opposing results and no change in lactulose/
mannitol ratio in food allergy (Kuitunen et al. 1994, Catassi et al. 1995). The 
conflicting results may be partly explained by the large biologic individual variation 
in lactulose/mannitol ratios. In addition, all infants have increased intestinal 
permeability, which then gradually decreases with age. This causes difficulties in 
the interpretation of lactulose/mannitol ratios in young children. Thus, it has not 
been possible to apply the findings of the lactulose-mannitol test for food allergy 
diagnosis in a reliable way suiting clinical practise. 
9.6.3.2. Increased urinary organic acid excretion in CMA: leaking intestine or  
 altered microbiota?
Consistent with the theory of the increased intestinal permeability in food allergies 
(Dupont et al. 1989), all urinary organic acids that differed significantly between 
eczema patients with and without CMA in our study were higher in CMA patients. 
Nevertheless, despite the changes in urinary organic acid excretion, infants with 
101
CMA in our study did not have other evidence of increased intestinal permeability, 
as their lactulose/mannitol ratio was similar to controls (Kuitunen et al. 2007). This 
suggests that the changes we noticed in urinary metabolic end products would be 
due to differences in intestinal bacterial metabolism rather than a general increase 
in intestinal permeability.
On the contrary, the effects of LGG treatment to urinary organic acids in CMA 
patients are suggestive of intestinal permeability playing a role in urinary organic 
acid excretion. Even if statistical significance was not reached in this small study 
population, the excretion of urinary organic acids decreased towards the control 
level after probiotic treatment. This supports the idea of the increased intestinal 
permeability related to food allergies being at least partly reversible. One could 
state that LGG treatment normalised intestinal flora and its metabolism. These 
results are, however, in line with the results of the lactulose-mannitol test, where 
LGG treatment reduced the permeability to mannitol in infants with CMA, and 
a similar trend was observed for the permeability to lactulose (Kuitunen et al. 
2007). Although not studied, it seems unlikely that changes in the composition or 
metabolism of intestinal flora would affect urinary lactulose and mannitol levels; 
instead, a change in intestinal permeability – due to low-grade inflammation 
induced by LGG, as Kuitunen et al. (2007) speculate – would be a more probable 
explanation.
The increase in urinary tartarate excretion that we noticed in patients with CMA 
is particularly interesting, as tartarate is not produced in human metabolism (Shaw 
et al. 1995). If confirmed in further studies, urinary tartarate could possibly serve 
as a marker for increased intestinal permeability and/or changes in microbial 
metabolism. Yeasts may produce tartarate (Shaw et al. 1995) and one could speculate 
that an explanatory factor for the elevated tartarate excretion in children with CMA 
would be intestinal yeast overgrowth due to changes in intestinal microbiota. It 
seems, however, that dietary intake still plays the most important part (Lord et al. 
2005) in human tartarate intake (and, possibly, excretion). 
If confirmed and specified with further research, the different patterns of urinary 
organic acid excretion between allergic and non-allergic infants could provide an 
innovative new approach to the diagnosis of CMA in infants.
9.6.3.3. Could urinary metabolic profiling distinguish between dierent   
 allergies?
If food allergies cause measurable metabolic and permeability changes in the 
intestine, these would probably not be allergen-specific; instead, the metabolic 
differences would be general markers of food intolerance leading to inflammation 
and altered microbial balance in the intestine. In our study with on average 6-month-
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old infants this was fairly well controlled, as in this age group, milk is by far the 
most important nutrient and if food intolerance in this age group is present, CMA is 
probable. As the differences in urinary metabolic profiles seemed to be reversible with 
LGG treatment, it would be interesting to study whether similar changes towards 
the control level would be seen after allergen (CM) elimination. An elimination – 
exposure –protocol with repeated urinary metabolic profile analyses could, then, 
help to distinguish between different allergens in subjects with a more varied diet.
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10. CONCLUSIONS
This thesis has focused on biochemical changes in both inherited and acquired 
situations with significant metabolic disturbances. These changes are seen as 
metabolic markers of the underlying pathogenetic processes, offering new insights 
into disease mechanisms and, with further research, even therapeutic potential. 
The main conclusions of the study are the following:
(1) Thiol metabolism is altered in children with several inherited metabolic 
diseases associated with defects in energy metabolism and nutrition. The 
changes in thiol metabolism in these metabolic diseases may partly be due 
to nutritional factors, but it seems that more complex disease mechanisms 
are involved.
(2) The alterations in plasma thiols and their redox state in organic acidaemias, 
mitochondrial diseases, hypoglycaemia and homocystinuria are suggestive 
of oxidative stress, which has previously been shown to play a role in the 
pathogenesis of complications of these diseases. As a new finding, the results 
of this series of studies show that oxidative stress may be present already 
at a stable phase of these metabolic diseases and thus truly contribute to 
the disease processes. 
(3) CMA is associated with measurable changes in urinary levels of end 
products of metabolism. These changes seem to reflect increased intestinal 
permeability and, possibly, differences in intestinal bacterial metabolism. 
The changes in urinary metabolic profile in CMA may also be seen as 
metabolic markers of inappropriate nutrition in early infancy. 
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